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ABSTRACT	Bcl-XL	 (B-cell-lymphoma-extra	 large)	 and	 the	 cell	 surface	 receptor	 CD44	 are	 two	proteins	involved	in	cancer.	Specifically,	the	anti-apoptotic	protein	Bcl-XL,	a	member	of	 the	 Bcl-2	 family,	 plays	 a	 key	 role	 in	 the	 maintenance	 of	 normal	 cellular	homeostasis.	However,	 its	overexpression	can	lead	to	oncogenic	transformation	and	it	is	responsible	for	drug	resistance	in	certain	types	of	cancer.	Structurally,	the	Bcl-2	family	is	characterized	by	the	presence	of	BH	domains,	which	are	involved	in	pivotal	protein-protein	 interactions.	 The	 anti-apoptotic	 protein	 Bcl-XL	 interacts	 through	 its	hydrophobic	pocket	with	the	BH3	domain	of	the	pro-apoptotic	members	of	the	Bcl-2	family,	 such	 as	Bak	 and	Bax.	 The	 inhibition	 of	 this	 interaction	 eventually	 promotes	cell	death.	The	cell	surface	receptor	CD44,	a	type	I	transmembrane	glycoprotein,	is	a	hyaluronan-binding	protein	expressed	on	the	surface	of	many	cell	 types,	where	it	 is	involved	 in	 leukocyte	 migration	 to	 inflamed	 sites,	 T-cell	 activation,	 and	 tumor	metastasis.	 Critical	 for	 these	 processes	 are	 the	 interactions	 between	 CD44	 and	 its	natural	ligand,	Hyaluronic	Acid	(HA).	The	involvement	of	CD44	in	cell	migration	and	its	 overexpression	 on	 a	 wide	 spectrum	 of	 tumor	 cells,	 make	 this	 receptor	 a	 good	target	 for	 drug	 design	 of	 new	 inhibitors	 and	 for	 delivery	 of	 chemotherapeutics	 to	cancer	cells.		In	the	first	part	of	thesis,	with	the	aim	of	identifying	an	inhibitor	of	Bcl-XL,	we	tested	a	small	library	of	fragments	against	Bcl-XL	using	solution	Nuclear	Magnetic	Resonance	(NMR)	spectroscopy.	Among	the	compounds	tested,	one	was	found	to	be	active	with	a	low	 millimolar	 Kd.	 Starting	 from	 this	 initial	 hit,	 we	 performed	 structure-activity	relationship	 (SAR)	 studies	 of	 several	 analogs	 using	 both	 protein-based	 NMR	experiments	 (mainly	 2D	 [1H,15N]-HSQC)	 and	 ligand-based	 NMR	 experiments	(Saturation	 Transfer	 Difference	 (STD)	 and	 waterLOGSY).	 Our	 studies	 led	 to	 a	 hit	
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fragment	with	a	Kd	of	811	μM,	calculated	using	the	chemical	shift	perturbations	(CSP)	from	 the	2D	 [1H,15N]-HSQC	 spectra.	Molecular	docking	 studies	performed	using	 the	experimentally	 obtained	 CSP	 information	 allowed	 us	 to	 obtain	 a	 low	 energy	conformation	 of	 the	 final	 fragment	 docked	 into	 the	 hydrophobic	 binding	 pocket	 of	Bcl-XL.	 The	second	part	of	this	thesis	regards	CD44,	a	protein	that	from	structural	data	is	not	a	particularly	druggable	 target	 and	only	 a	 few	putative	 ligand	agents	 are	known	 to	bind	it	in	cellular	assays.	We	first	attempted	to	validate	these	putative	ligand	agents	with	biophysical	methods,	but	surprisingly	we	 found	that,	with	 the	exception	of	HA	and	a	commercially	available	antibody,	none	of	these	bound	recombinant	hCD44(21-178)	appreciably.	In	the	pursuit	of	possible	novel	CD44	antagonists,	we	performed	a	fragment	 screening	 campaign	 on	 15N-hCD44(21-178)	 using	1D	1H-aliphatic	 and	2D	[1H,15N]-sofastHMQC	NMR	experiments.	We	found	two	initial	structurally	related	hits	and	starting	from	these,	further	studies	were	performed	using	commercially	available	analogues.	These	experiments	resulted	in	a	fragment	hit	with	a	dissociation	constant	calculated	 using	 the	 chemical	 shift	 perturbation	 from	 the	 2D	 [1H,15N]-sofastHMQC	spectra	of	7.43	mM.		In	conclusion	Bcl-XL	and	CD44	are	both	overexpressed	in	many	types	of	cancer	cells.	Hence,	finding	ligand	agents	able	to	inhibit	these	two	proteins	is	very	a	appealing	task	for	 the	 development	 of	 new	 chemotherapeutics.	 Using	 a	 fragment-based	 by	 NMR	approach,	we	found	two	hits	 for	each	target,	which	could	be	at	the	basis	 for	 further	fragment	evolution	studies	for	the	development	of	more	potent	lead	compounds.	 	
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RIASSUNTO	Bcl-XL	 (B-cell-lymphoma-extra	 large)	 e	 il	 recettore	 transmembrana	CD44,	 sono	due	proteine	 coinvolte	 nel	 cancro.	 In	 particolare,	 la	 proteina	 anti-apoptotica	 Bcl-XL,	membro	 della	 famiglia	 di	 Bcl-2,	 gioca	 un	 ruolo	 chiave	 nel	 mantenimento	 della	normale	 omeostasi	 cellulare.	 Tuttavia,	 la	 sua	 sovraespressione	 può	 portare	 alla	trasformazione	oncogenica	ed	è	responsabile	per	la	resistenza	ai	farmaci	in	alcuni	tipi	di	cancro.	Strutturalmente,	questa	famiglia	è	caratterizzata	dalla	presenza	di	domini	BH,	 che	 sono	 coinvolti	 in	 fondamentali	 interazioni	 proteina-proteina.	 La	 proteina	anti-apoptotica	 Bcl-XL	 interagisce	 attraverso	 la	 sua	 tasca	 idrofobica	 con	 il	 dominio	BH3	dei	membri	pro-apoptotici	della	famiglia	Bcl-2,	come	BAK	e	BAX.	L'inibizione	di	questa	 interazione	 favorisce	 infine	 la	 morte	 cellulare.	 Il	 recettore	 di	 superficie	cellulare	CD44,	è	una	glicoproteina	di	transmembrana	di	tipo	I,	ed	è	una	proteina	che	lega	 l’acido	 ialuronico	 espresso	 sulla	 superficie	 di	 molti	 tipi	 di	 cellule,	 in	 cui	 è	coinvolta	nella	migrazione	dei	leucociti	ai	siti	di	infiammazione,	nell’attivazione	delle	cellule	T	e	nelle	metastasi	tumorali.	Critico	per	questi	processi	sono	le	interazioni	tra	CD44	 e	 il	 suo	 ligando	 naturale,	 l’acido	 ialuronico	 (HA).	 Il	 coinvolgimento	 di	 CD44	nella	migrazione	 cellulare	 e	 la	 sua	 sovraespressione	 su	 un	 ampio	 spettro	 di	 cellule	tumorali,	 rendono	questo	recettore	un	buon	bersaglio	per	 la	progettazione	di	nuovi	farmaci	e	per	il	drug	delivery	di	chemioterapici	in	cellule	tumorali.	Nella	 prima	 parte	 della	 tesi,	 con	 l'obiettivo	 di	 individuare	 un	 inibitore	 di	 Bcl-XL,	abbiamo	 testato	 una	 piccola	 libreria	 di	 frammenti	 contro	 Bcl-XL	 utilizzando	 come	tecnica	 la	 spettroscopia	 di	 Risonanza	 Magnetica	 Nucleare	 (NMR)	 in	 soluzione.	 Tra	questi	 uno	 è	 risultato	 essere	 attivo	 con	 una	Kd	 nel	 basso	millimolare.	 Partendo	 da	questo	hit	iniziale,	abbiamo	effettuato	degli	studi	di	relazione	struttura-attività	(SAR)	di	 diversi	 analoghi,	 utilizzando	 sia	 esperimenti	 NMR	 che	 guardano	 alla	 proteina	
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(soprattutto	 2D	 [1H,	 15N]	 -HSQC)	 ed	 esperimenti	 NMR	 concentrati	 sul	 ligando	(Saturation	Transfer	Difference	(STD)	e	waterLOGSY).	I	nostri	studi	hanno	portato	ad	un	frammento	con	un	Kd	di	811	μM	calcolati	utilizzando	le	perturbazioni	di	chemical	shift	 (CSP)	 dagli	 spettri	 2D	 [1H,	 15N]-HSQC.	 Dagli	 studi	 di	 docking	 molecolare	condotti	 utilizzando	 le	 informazioni	 di	 CSP	 sperimentalmente	 ottenute,	 ci	 hanno	permesso	di	ottenere	una	conformazione	a	bassa	energia	del	frammento	finale	nella	tasca	di	legame	idrofobica	di	Bcl-XL.	La	seconda	parte	di	questa	 tesi	 riguarda	CD44,	una	proteina	che	dai	dati	strutturali	non	è	un	target	particolarmente	‘druggable’	e	solo	pochi	agenti	leganti	sono	noti	per	legarla	 in	 saggi	 cellulari.	 Per	 prima	 cosa	 abbiamo	 cercato	 di	 convalidare	 tali	 agenti	leganti	 noti	 con	metodi	 biofisici,	 ma	 sorprendentemente	 abbiamo	 trovato	 che,	 con	l'eccezione	 di	 HA	 e	 un	 anticorpo	 disponibile	 in	 commercio,	 nessuno	 di	 questi	 lega	apprezzabilmente	 la	 proteina	 ricombinante	 hCD44(21-178).	 Nel	 perseguire	 dei	possibili	nuovi	antagonisti	di	CD44	abbiamo	effettuato	una	campagna	di	screening	di	frammenti	sulla	proteina	15N-hCD44(21-	178)	utilizzando	esperimenti	NMR	1D	1H-alifatici	 e	 2D	 [1H,	 15N]-sofastHMQC	 come	metodi	 di	 rilevamento.	 Abbiamo	 trovato	due	 hit	 iniziali	 strutturalmente	 affini	 e	 partendo	 da	 questi	 abbiamo	 effettuato	ulteriori	 studi	 utilizzando	 analoghi	 disponibili	 in	 commercio.	 Questi	 esperimenti	hanno	 portato	 in	 un	 frammento	 con	 una	 costante	 di	 dissociazione	 calcolata	 con	 la	perturbazione	di	chemical	shift	dagli	esperimenti	2D	[1H,	15N]-sofastHMQC		di	7,43	mM.	In	 conclusione	 Bcl-XL	 e	 CD44	 sono	 entrambe	 sovraespresse	 in	 molti	 tipi	 di	 cellule	tumorali.	 Per	 questo	 motivo	 trovare	 agenti	 leganti	 capaci	 di	 inibire	 queste	 due	proteine	 è	 un	 compito	 molto	 attraente	 per	 lo	 sviluppo	 di	 nuovi	 chemioterapici.	Utilizzando	un	approccio	NMR	basato	sui	frammenti,	abbiamo	trovato	per	entrambi	i	
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target	 due	 hit	 che	 potrebbero	 essere	 la	 base	 per	 ulteriori	 studi	 di	 evoluzione	 del	frammento	per	lo	sviluppo	di	composti	lead	più	potenti.	
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Chapter	1	
Introduction	
	B-cell-lymphoma-extra	 large	 (Bcl-XL)	 is	 a	 transmembrane	 protein	 present	 on	 the	mitochondria.	 In	humans	 is	encoded	by	the	BCL2L1	gene	that	encodes	a	233	amino	acid	protein	(Figure	1).	It	is	one	of	the	many	anti-apoptotic	proteins	belonging	to	the	Bcl-2	family,	and	it	is	implicated	on	the	survival	of	tumor	cells.	The	homology	with	the	other	 members	 of	 the	 Bcl-2	 family	 is	 guaranteed	 by	 the	 presence	 of	 four	 Bcl-2	Homologue	 (BH)	 domains	 that	 are	 fundamental	 for	 protein-protein	 interactions	between	Bcl-2	family	members.			
	
Figure	1	Amino	acid	sequence	of	human	Bcl-XL	
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Bcl-2	family	The	peculiarity	of	this	family	resides	in	the	high	structural	homology	guaranteed	by	the	presence	of	particular	domains	called	BH	domains[1].	Four	BH	domains	have	been	identified,	commonly	called	BH1,	BH2,	BH3,	and	BH4.	A	common	classification	of	the	Bcl-2	 family	 members	 could	 be	 done	 based	 on	 the	 ability	 to	 induce	 or	 prevent	apoptosis,	 and	 using	 this	 criterion,	 the	 proteins	 are	 divided	 into	 pro-apoptotic	 and	anti-apoptotic	proteins,	respectively,	as	reported	in	Figure	2[2].		
	
Figure	2	Classification	in	pro-apoptotic	and	anti-apoptotic	subfamilies	of	the	most	important	members	of	the	Bcl-2	protein	family.	Green	bars	indicate	the	segments	with	α-helix	structure.	The	red	 lines	 label	regions	of	 transmembrane	domain	(TM).	The	homology	regions	are	also	shown:	BH1	(brown	 lines),	BH2	(gray	 lines),	BH3	(blue	 lines),	 and	BH4	(orange	 lines).	The	BH1,	BH2,	and	BH3	domains	are	folded	to	form	a	hydrophobic	pocket	that	can	bind	BH3-only	
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peptides.	 The	 first	 five	 proteins	 are	 normally	 anti-apoptotic.	 The	 three	 proteins	 in	 the	highlighted	 area	 have	 not	 been	 studied	 much	 and	 cannot	 yet	 be	 categorized.	 The	 last	 12	proteins	are	considered	pro-apoptotic	[2].		The	anti-apoptotic	proteins	are	multi-BH,	and	usually	possess	all	four	BH	domains,	as	in	 the	 case	 of	 Bcl-XL.	 The	 pro-apoptotic	 proteins	 could	 be	 in	 turn	 subdivided	 into	multi-BH,	and	BH3-only	proteins,	depending	on	the	presence	of	all	the	BH	domains	or	only	BH3.	Pro-apoptotic	family	members	that	contain	BH1	and	BH2	regions,	such	as	Bax,	 can	 promote	 apoptosis	 through	 their	 interactions	 with	 mitochondrial	membranes.	 This	 activity	 is	 independent	 of	 their	 ability	 to	 interact	 with	 anti-apoptotic	proteins.	The	BH3	region	is	responsible	for	mediating	the	interactions	with	anti-apoptotic	 proteins	 and	 for	 the	 ability	 of	 the	 proteins	 to	 promote	 programmed	cell	death[3].	Since	 its	 discovery,	 the	 role	 of	 Bcl-2	 was	 associated	 with	 apoptosis.	 Actually,	 it	 is	known	that	the	Bcl-2	family	proteins	regulate	all	major	types	of	cell	death,	including	apoptosis,	necrosis,	and	autophagy	[4].	The	 mechanisms	 that	 regulate	 tissue	 homeostasis	 are	 governed	 mainly,	 but	 not	exclusively,	by	the	proteins	of	the	Bcl-2	family.	The	daily	programmed	cell	death,	 in	the	 majority	 of	 tissues,	 involves	 the	 mitochondria,	 organelles	 that,	 in	 addition	 to	producing	energy,	play	a	critical	role	 in	regulating	the	balance	between	 life	and	cell	death[5].	The	pro-apoptotic	proteins	of	the	Bcl-2	family,	such	as	Bax	and	Bak,	induce	mitochondrial	 outer	 membrane	 permeabilization,	 causing	 the	 release	 of	 caspase-activating	 proteins	 and	 other	 mediators	 of	 cell	 death.	 The	 anti-apoptotic	 proteins,	such	 as	 Bcl-2,	 Mcl-1	 and	 Bcl-XL,	 act	 as	 'guardians'	 of	 the	 outer	 membrane	 and	preserve	its	integrity	by	binding	to	Bax	and	Bak	and	preventing	them	from	carrying	out	their	function[6].	Many	theories	have	been	reported	on	the	molecular	mechanism	
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that	leads	to	apoptosis,	but	the	exact	molecular	process	is	not	fully	clear	yet.	The	key	point	 is,	 however,	 the	 interaction	 between	 the	 different	 members	 of	 the	 family	 to	promote	or	inhibit	apoptosis,	highlighting	one	of	the	most	distinctive	features	of	this	family:	the	ability	to	form	specific	protein-protein	interactions.		
Structure	of	Bcl-XL	Bcl-XL	is	a	233	residues	protein	and,	as	shown	in	Figure	3,	consists	of	two	central	α-helices	(α5	and	α6),	which	are	about	30	Å	long	and	are	flanked	on	one	side	by	helices	α3	and	α4	and	on	 the	other	 side	by	α1,	α2	and	α7.	The	 two	central	helices	 contain	predominantly	 hydrophobic	 residues	 and	 are	 arranged	 in	 an	 antiparallel	 way.	 The	presence	 of	 a	 proline	 in	 position	 180	 inside	 the	 α6	 helix	 causes	 a	 change	 in	 the	direction	 of	 this	 helix.	 The	 C-terminal	 helix	 (α7)	 is	 connected	 to	 α6	 through	 an	irregular	 turn	 composed	 of	 two	 glycines	 (G186	 and	 G187)	 that	 are	 highly	conserved[7].	 The	 N-terminal	 helix	 forms	 numerous	 hydrophobic	 interactions	 with	helices	 α2,	 α5	 and	 α6	 that	 seem	 to	 be	 important	 for	 structural	 stability	 [7].	 Some	proteins	of	the	Bcl-2	family	share	homologous	BH1	and	BH2	domains	and	mutations	of	 Bcl-2	 or	 Bcl-XL	 in	 these	 regions	 abolish	 the	 anti-apoptotic	 activity	 and	 block	 the	hetero-dimerization	 with	 other	 members	 of	 the	 Bcl-2	 family	 (Bax	 or	 Bak)	 that	promote	programmed	cell	death.	A	third	region	characterized	by	structural	homology	between	the	proteins	of	the	family	is	the	BH3	domain,	recognized	to	be	essential	for	the	 activity	 of	 proteins	 that	 promote	 cell	 death.	 These	 regions	 with	 an	 important	function	 (BH1,	BH2	and	BH3)	are	 in	close	spatial	proximity,	and	 form	an	elongated	hydrophobic	pocket	in	Bcl-XL,	which	is	the	site	of	interaction	with	proteins	promoting	cell	 death.	Helix	 α1	 is	 connected	 to	α2	 through	 a	 flexible	 loop	of	 approximately	 60	residues	 not	 essential	 for	 the	 anti-apoptotic	 activity[7].	 Like	many	 other	 proteins	 of	
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the	Bcl-2	family,	Bcl-XL	contains	a	C-terminal	transmembrane	domain,	the	function	of	which	is	to	anchor	Bcl-XL	to	various	intracellular	membranes,	in	particular	the	outer	mitochondrial	membrane	[7].	
	
Figure	 3	 Crystallographic	 structure	 of	 Bcl-XL	 (PDB	 ID	 2BZW),	 shown	 with	 the	 secondary	structure	(α-helices	in	red,	and	β-turn	in	blue)		
Protein-protein	interactions	The	hydrophobic	pocket	of	Bcl-XL	is	able	 to	bind	 the	BH3	domain	consisting	of	a	α-helix.	 The	 binding	 interface	 of	 BH3	 peptides	 is	 based	 on	 the	 conservation	 of	 some	hydrophobic	residues	(specifically,	a	Phe	and	a	Leu)	that	are	placed	into	two	cavities	in	 the	hydrophobic	 site	 of	Bcl-XL.	 In	 addition,	 an	Asp	 residue,	 conserved	 in	 all	BH3	domains,	establishes	a	polar	bond	with	an	Arg	present	in	α5	(Figure	4). 	
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Figure	 4	 Superposition	 of	 two	 different	 BH3	 domains	 arising	 from	 BIM	 and	 BAD,	 co-crystallized	with	Bcl-XL	(PDB	ID	1PQ1	and	2BZW	of	BIM	and	BAD,	respectively).	The	surface	of	 the	 hydrophobic	 pocket	 of	 Bcl-XL	 is	 color-coded	 according	 to	 the	 characteristics	 of	lipophilicity	(Green:	hydrophobic;	Blue:	mildly	polar;	Purple:	H-bonding	area).	The	backbone	of	the	BH3	peptides	and	the	residues	important	for	interaction	are	colored	in	yellow	and	red	(BIM	and	BAD,	respectively). 	
Physiological	role	of	Bcl-XL	The	 most	 important	 role	 of	 Bcl-XL	 is	 related	 to	 its	 ability	 to	 promote	 survival	 in	various	cell	 lines	involved	in	the	apoptotic	process.	The	exact	molecular	mechanism	by	which	Bcl-XL	promotes	 cell	 survival	 is	 not	 fully	understood,	 but	 it	 is	 believed	 to	involve	 the	suppression	of	 the	release	of	cytochrome	c	 from	mitochondria,	possibly	through	heterodimerization	with	 the	neutralization	of	pro-apoptotic	proteins	of	 the	Bcl-2	family.	The	main	model	to	explain	the	regulation	of	apoptosis	through	Bcl-XL	is	the	model	of	movement	(or	indirect	activation):	the	main	feature	is	that	the	multi-BH	pro-apoptotic	 proteins	 Bax	 and	 Bak	 are	 constitutively	 active	 and	 must	 be	continuously	 bound	 and	 inhibited	 by	 Bcl-XL	 for	 cell	 survival[8].	When	 the	 apoptotic	signal	 is	 received,	 the	 BH3-only	 proteins	 (Bim,	 tBID,	 Bik,	 PUMA,	 and	 NOXA)	competitively	 bind	 to	 the	 hydrophobic	 site	 of	 Bcl-XL	 displacing	Bax	 and	Bak[9].	 The	
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released	 monomers	 of	 Bax	 and	 Bak	 may	 then	 interact	 with	 each	 other	 through	oligomerization	 and	 form	 pores	 that	 allow	 the	 permeabilization	 of	 the	 outer	mitochondrial	membrane.	At	this	point,	cytochrome	c	is	released	from	mitochondria	and	activates	a	cascade	of	caspases	allowing	the	cleavage	of	specific	cellular	proteins,	eventually	leading	to	cell	death[10].	In	this	model,	it	is	clear	that	Bcl-XL	plays	an	anti-apoptotic	role	by	sequestering	the	pro-apoptotic	proteins	in	the	outer	mitochondrial	membrane,	thus	preventing	the	oligomerization	of	Bak/Bax	(Figure	5). 
	
Figure	5	General	apoptosis-regulating	mechanism	mediated	by	the	Bcl-2	family	members	to	which	 also	Bcl-XL	 belongs.	Upon	 interactions	between	proteins	of	 the	 family,	 pro-apoptotic	factors	such	as	cytochrome	c	are	released	that	contribute	to	the	formation	of	the	apoptosome	and	the	subsequent	activation	of	caspases.		
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Diseases	related	to	Bcl-XL	In	 physiological	 conditions,	 apoptosis	 ensures	 the	 homeostasis	 of	 tissues	 by	maintaining	 the	 number	 of	 cells	 constant.	 On	 the	 other	 hand,	 dysregulation	 of	apoptosis	 produces	 wide-ranging	 effects	 in	 many	 patho-physiologies.	 An	 excess	 of	apoptosis	 is	 implicated	 in	 several	neurodegenerative	disorders	 such	as	Alzheimer's	disease	 and	 multiple	 sclerosis	 while	 the	 lack	 of	 apoptosis	 is	 a	 central	 step	 in	oncogenesis	 and	 many	 inflammatory	 conditions[11].	 Overexpression	 of	 Bcl-XL	 is	related	to	several	diseases,	including	particularly	aggressive	cancers.		
Fragment-Based	Drug	Design	of	Bcl-XL	inhibitors	The	Fragment-Based	Drug	Design	(FBDD)	approach	has	been	developed	mainly	in	the	last	10	years	and	 is	now	recognized	as	a	particularly	 effective	methodology	 in	 lead	discovery.	 The	method	was	 proposed	 by	 Abbot	 in	 1996	 and	 has	 gained	 increasing	interest	 over	 the	 years	 to	 become	 a	 real	 alternative	 to	 high-throughput	 screening.	Strategies	based	on	FBDD	are	now	routinely	used	in	many	pharmaceutical	companies	and	have	already	yielded	promising	results.	The	method	consists	in	the	screening	of	a	small	set	of	compounds	of	low	molecular	weight	(<300Da),	called	fragments.	Because	of	 their	 low	 complexity,	 the	 fragments	 normally	 show	 low	 affinity	 for	 the	 target	protein,	but	optimization	of	 the	 fragments	 identified,	normally	through	the	addition	of	new	chemical	moieties	or	alternatively	by	connecting	two	fragments	 that	bind	to	adjacent	 sites,	 can	 lead	 to	 very	 interesting	 compounds,	 as	 demonstrated	 in	 the	literature[12]	(Figure	6). This	method	of	 'lead-conception'	relies	on	the	premise	that	the	binding	site	and	the	way	of	binding	of	the	fragments	should	be	retained	in	case	of	fragment	modification,	
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and	 when	 two	 fragments	 are	 linked	 together,	 their	 orientation	 in	 their	 respective	binding	sites	should	remain	the	same[12]. 
	
Figure	 6	 In	 the	Fragment-Based	Drug	Design,	a	screening	of	a	 library	of	 fragments	 is	done	(eg.	through	NMR)	to	find	those	that	bind	into	sub-pocket	of	the	binding	surface	of	the	target	protein.	The	fragments	are	then	linked	together	to	make	a	larger	molecule	that	binds	better	to	the	binding	pocket	of	the	target	protein.		The	 screening	 techniques	 most	 commonly	 used	 in	 the	 literature	 are	 the	 solution	Nuclear	Magnetic	Resonance	(NMR),	 the	X-ray	crystallography,	 the	Surface	Plasmon	Resonance	(SPR),	and	some	biochemical	assays.	The	NMR	is	the	technique	of	choice	in	 screening	 of	 fragments	 because	 it	 is	 a	 technique	 particularly	 sensitive	 to	intermolecular	 interactions	 of	 low	 affinity,	 typical	 for	 small	 molecules	 (affinity	constants	 in	 the	 order	 of	 low	 millimolar).	 Furthermore,	 compared	 with	 other	techniques,	thorough	the	NMR	can	be	derived	structural	data,	and	is	also	very	robust,	returning	a	low	rate	of	false-positives[13]	[14].	ABT-737	 (Figure	 7A)	 is	 a	 small	 molecule	 developed	 as	 a	 binder	 of	 some	 anti-apoptotic	proteins	of	 the	Bcl-2	 family,	 including	Bcl-XL	(Figure	 7B),	which,	by	upon	binding	to	it,	promotes	the	oligomerization	of	Bax	and	Bak	causing	programmed	cell	death	 of	 malignant	 cells.	 ABT-737	 was	 developed	 by	 Abbott	 Laboratories	 using	 a	screening	 of	 fragments	 by	 Nuclear	 Magnetic	 Resonance,	 and	 is	 the	 result	 of	 the	
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binding	of	two	different	small	molecules	of	weak	affinity	to	give	a	single	molecule	of	high	 affinity[15].	 However	 ABT-737	 is	 not	 suitable	 as	 a	 drug	 for	 human	 treatment	because	 of	 its	 toxicity	 in	 humans,	 but	 it	 has	 opened	 a	 process	 field	 for	 the	development	of	new	molecules	derived	from	it,	still	in	experimentation.	
	
Figure	7	(A)	Chemical	structure	of	ABT-737;	(B)	Bcl-XL	co-crystallized	with	ABT-737	(PDB	ID	2YXJ).	 The	 surface	 of	 Bcl-XL	 is	 color-coded	 according	 to	 the	 characteristics	 of	 lipophilicity	(Green:	hydrophobic;	Blue:	mildly	polar;	Purple:	H-bonding	area).																				
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Methods	and	Materials	
	
Protein	expression	and	purification	The	use	of	NMR	spectroscopy	requires	a	substantial	amount	of	very	pure	protein.	For	this	reason,	the	protein	was	produced	through	biotechnological	techniques	using	an	
E.	 coli	 expression	 system.	 	 The	 cDNA	 of	 human	 Bcl-XL	 ΔTM	 was	 cloned	 into	 an	expression	 plasmid	 pET15b	 and	 introduced	 into	 E.	 coli	 BL21	 (DE3)	 strain.	 The	expression	 product	 contained	 an	 N-terminal	 His-tag,	 a	 sequence	 of	 cleavage	 for	thrombin,	 and	 the	 sequence	 coding	 for	 Bcl-XL,	 except	 for	 the	 last	 24	 amino	 acids,	which	constitute	the	transmembrane	domain.	The	overexpression	of	the	protein	was	obtained	in	E.	coli	BL21	(DE3),	by	growing	the	bacteria	in	LB	medium	at	37	°C	in	the	presence	of	 the	 antibiotic	 ampicillin	until	 an	OD600	of	0.6	was	 reached,	 followed	by	induction	with	0.6	mM	isopropyl	β-D-thiogalactopyranoside	(IPTG).	After	4	hours,	the	cells	were	harvested	by	centrifugation,	resuspended	in		25	mM	Tris-HCl	buffer	pH	=	8,	and	sonicated.	After	a	further	centrifugation	step,	the	soluble	fraction,	containing	Bcl-XL,	was	purified	through	a	nickel	affinity	column	(His-Trap)	using	an	FPLC	system.	To	obtain	 the	monomer	 fraction	with	greater	purity,	 a	 further	 step	of	purification	was	carried	out	by	means	of	size	exclusion	chromatography	(gel	filtration)	using	a	HiLoad	16/60	Superdex	75	column	in	20	mM	Tris-HCl	buffer	at	pH	7.4,	1	mM	DTT,	and	150	mM	 NaCl.	 For	 the	 expression	 of	 the	 15N-labeled	 protein	 used	 in	 the	 2D-NMR	experiments,	 the	 procedure	 was	 the	 same,	 but	 the	 bacteria	 were	 grown	 in	 M9	minimal	medium	supplemented	with	1	g/L	 15NH4Cl	 for	 labeling	purposes.	The	pure	protein	was	 stored	at	 a	 concentration	of	40	µM	at	 -80	 °C.	The	 concentration	of	 the	
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protein	was	 estimated	 through	 UV	 spectroscopy	measuring	 the	 absorbance	 at	 280	nm,	using	the	molar	extinction	coefficient	ε	=	47440	M-1cm-1.		
Nuclear	Magnetic	Resonance	(NMR)	Nuclear	magnetic	resonance	(NMR)	is	one	of	the	most	powerful	analytical	techniques	present	 in	 chemistry,	 and	 together	 with	 X-ray	 crystallography,	 is	 the	 technique	 of	choice	for	protein	structure	determination	at	high	resolution.	The	advantages	of	NMR	are	 the	 possibility	 to	 study	 macromolecules	 in	 solution	 (conditions	 closer	 to	physiological	ones)	and	the	possibility	to	study	the	dynamic	behavior	of	the	protein.	Over	 9000	 NMR	 structures	 are	 deposited	 in	 the	 Protein	 Data	 Bank	 (PDB).	 Despite	these	 advantages,	 the	NMR	 can	 be	 applied	 only	 to	 proteins	 of	 a	 certain	 number	 of	amino	acids;	proteins	above	40	kDa	are	difficult	 to	study	 through	classic	strategies,	because	of	their	relaxation	properties.		
One-dimensional	1H	-NMR	experiment	The	nucleus	most	widely	investigated	by	NMR	is	1H,	as	a	result	of	several	factors:	1H	is	abundant	 in	nature,	 the	hydrogen	 forms	a	wide	range	of	compounds	with	a	 large	number	 of	 elements,	 it	 is	 a	 fermion	 (non	 zero	 spin),	 and	 has	 a	 high	 gyromagnetic	ratio,	 which	 is	 related	 to	 the	 intensity	 of	 the	 signal.	 Experiments	 based	 on	 proton	allow	 the	 study	 of	 small	 molecules	 and	 small	 peptides.	 In	 the	 study	 of	 proteins,	homonuclear	experiments	based	on	hydrogen	are	useful	as	fingerprints	to	identify	a	protein	or	 to	check	 for	chemical	shift	perturbation	 in	 the	more	shielded	area	of	 the	spectrum.			
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Two-dimensional	spectroscopy	Peptides	are	characterized	by	the	presence	of	many	protons	in	their	structure	and	it	is	easy	to	understand	that	even	short	sequences	generate	a	certain	number	of	peaks	that	may	lie	in	the	same	region	of	the	spectrum.	As	the	size	of	the	peptide	increases,	more	 and	 more	 resonances	 become	 degenerate,	 and	 it	 is	 impossible	 to	 assign	 the	signals	using	one-dimensional	techniques.	In	a	two-dimensional	NMR	experiment,	the	signal	 is	 registered	as	a	 function	of	 two	 time	variables,	 t1	and	 t2,	 and	 the	 resulting	data	are	subjected	to	two	Fourier	transforms	to	obtain	the	spectrum	as	a	function	of	two	frequency	variables.	In	Figure	8,	 the	general	scheme	for	two-dimensional	NMR	spectroscopy	is	shown.	
	
Figure	8	General	pulse	sequence	of	a	2D	NMR	experiment			In	the	first	part,	called	preparation	time,	the	sample	is	excited	by	one	or	more	pulses.	The	 net	 magnetization	 is	 left	 to	 evolve	 during	 the	 evolution	 period,	 t1.	 Then,	 the	mixing	time	follows,	consisting	in	a	further	series	of	pulses,	the	purpose	of	which	is	to	transfer	the	magnetization	between	different	nuclei.	After	the	mixing	time,	the	signal	is	recorded	as	a	function	of	the	second	time	variable	(t2).	This	sequence	of	events	is	called	 pulse	 sequence	 and	 the	 exact	 nature	 of	 the	 preparation	 and	mixing	 periods	determines	the	information	obtainable	in	the	NMR	spectrum[16].		
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Heteronuclear	experiments	As	 it	 is	 possible	 to	 detect	 correlations	 through	 J-coupled	 proton	 spins,	 it	 is	 also	possible	to	observe	correlations	between	protons	and	different	nuclei	with	non-zero	spin,	 such	 as	 nitrogen	 and	 carbon,	 to	 which	 the	 protons	 themselves	 are	 coupled	(heteronuclear	 J-correlated	 spectroscopy).	 In	 the	 case	 of	 NMR	 of	 proteins,	 the	isotopes	 13C	 and	 15N	 are	 particularly	 important,	 as	 they	 have	 spin	 1/2.	 In	 a	heteronuclear	 NMR	 spectrum,	 along	 one	 axis	 are	 the	 proton	 chemical	 shifts,	 and	along	the	other	axis	the	chemical	shifts	of	the	heteronucleus.	Each	peak	identifies	the	scalar	 correlation	 between	 a	 particular	 proton-heteronucleus	 pair.	 The	 wide	dispersion	 of	 heteronuclear	 chemical	 shifts	 allows	 the	 overlaps	 between	 different	peaks	 to	be	reduced,	and	this	 is	particularly	 important	 in	 the	study	of	proteins	 that	have	a	large	number	of	signals.	Because	the	proteins	are	mainly	composed	of	C,	N,	H,	and	O,	the	importance	of	techniques	able	to	give	information	between	nuclei	different	from	proton	is	evident.	In	Table	1,	it	can	be	seen	that	only	isotopes	13C	and	15N	have	spin	1/2,	and	so	they	are	ideal	for	study	through	NMR.	However,	these	isotopes	have	low	natural	abundance	and	need	to	be	artificially	introduced	into	the	macromolecule	to	be	studied	by	NMR.		
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Table	1	NMR	properties	of	some	nuclei	
	
	Nowadays,	 the	 expression	 of	 isotopically	 labeled	 proteins	 is	 a	 common	 strategy	carried	out	in	many	laboratories.	The	NMR	samples	require	a	large	amount	of		protein	to	reach	the	ideal	concentration	for	this	technique.	The	easiest	and	cheapest	strategy	to	obtain	them	is	the	expression	and	subsequent	purification	using	bacterial	vectors,	such	 as	E.	coli.	With	 this	 approach,	 it	 is	 possible	 in	 the	 first	 place	 to	 produce	 large	amounts	 of	 protein,	 and	 also	 to	 express	 proteins	 enriched	 with	 13C	 and	 15N	 using	specific	media	containing	15NH4Cl	as	sole	nitrogen	source,	and	13C-glucose	as	carbon	source.	One	of	the	main	problems	of	heteronuclear	NMR	is	the	relative	sensitivity	of	
13C	and	15N	nuclei,	such	that	the	direct	detection	of	these	nuclei	can	be	problematic.	The	 population	 difference	 (at	 Boltzmann	 equilibrium)	 is	 proportional	 to	 the	gyromagnetic	ratio	γ.	The	relative	sensitivity	of	nucleus	X	with	respect	to	the	proton	is	defined	as:	
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!! = !!! !! = !!!!!(! + 1)! !! ! !!! 12+ 1 	Where	 SX	 and	! !! 	are	 the	 signal	 to	 noise	 ratio	 of	 the	 heteronucleus	 X,	 and	 1H,	respectively,	and	N	is	the	natural	abundance	of	the	nuclei.	Neglecting	the	term	due	to	the	natural	abundance	(e.g.,	proteins	uniformly	enriched	with	13C	and	15N),	for	nuclei	with	spin	1/2	the	sensitivity	relative	to	1H	is	given	by:	
!! = !!! !! !	For	 13C	 and	 15N,	 the	 relative	 sensitivity	 are	1.6×10!!,	 and	1.0×10!!	respectively.	Nowadays,	 the	 strategy	used	 to	 resolve	 the	 problem	of	 sensitivity	 in	 heteronuclear	experiments	is	to	excite	and	observe	always	the	magnetization	of	the	most	sensitive	nucleus	(1H),	and	to	transfer	the	same	magnetization	to	the	heteronucleus	and	back	during	the	pulse	sequence	to	detect	its	resonance	frequency	indirectly.		
Insensitive	Nuclei	Enhanced	by	Polarization	Transfer:	INEPT	The	INEPT	(Insensitive	Nuclei	Enhanced	by	Polarization	Transfer)[17]	sequence	is	the	basic	 building	 block	 of	 many	 heteronuclear	 NMR	 experiments	 correlating	 protons	and	heteronuclei	 that	 are	 coupled	 together.	Basically,	 the	 INEPT	 consist	 to	 transfer	the	magnetization	 from	a	sensitive	nucleus	with	a	high	gyromagnetic	 ratio	 (such	as	proton)	to	less	sensitive	nuclei	with	a	low	gyromagnetic	ratio	(such	as	nitrogen	and	carbon),	through	the	scalar	coupling	interaction.	In	Figure	9[18]	the	vector	representation	of	the	magnetization	during	the	INEPT	pulse	sequence	is	shown.	The	first	90°	1H	pulse	rotates	the	1H	magnetization	onto	the	y-axis	at	 point	 a.	 After	 the	 first	 1/(4JCH)	 delay	 (here	 carbon	 is	 taken	 as	 an	 example,	 but	generally	 is	 1/(4JXH),	 where	 X	 is	 the	 less	 sensitive	 heteronucleus),	 each	 of	 the	
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doublets	 caused	 by	 the	 JCH	 coupling	 is	 45°	 away	 from	 the	 y-axis.	 The	 simultaneous	180°	pulses	on	both	 1H	and	13C	refocus	 the	chemical	 shift	but	allow	the	coupled	 1H	vectors	to	continue	to	diverge.	This	can	be	understood	by	considering	the	effect	of	the	
1H	and	13C	180°	pulses	individually.	After	the	1H	180°	pulse	flips	the	doublets	about	the	x-axis,	the	13C	180°	inverts	the	population	of	13C	states	of	the	coupled	doublets	but	has	no	effect	on	uncoupled	chemical	shift.	Consequently,	the	magnetization	in	the	13C	α	state	becomes	that	in	the	β	state,	and	vice	versa.	In	the	vector	diagram	at	point	c,	it	is	shown	that	the	slower	and	faster	vectors	exchange	places,	resulting	in	the	vectors	rotating	in	the	opposite	direction	(c).		After	the	second	1/(4JCH)	delay,	the	two	vectors	are	180°	out	of	phase	and	aligned	on	the	x-axis	(d).	The	following	1H	90°	pulse	rotates	the	1H	magnetization	components	back	to	the	z	and	–z	axes	(e),	and	the	13C	90°	pulse	brings	the	coupled	magnetization	components	back	to	the	xy	plane,	which	results	in	detectable	anti-phase	magnetization	(f)[18].		
	
Figure	9	Vector	representation	of	an	INEPT	experiment.	The	narrow	and	wide	bars	are	90°	and	180°	pulses,	respectively.	All	pulses	are	x	phase	except	the	last	1H	90°	y.			
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HSQC	experiment	(Heteronuclear	Single-Quantum	Coherence)	The	HSQC	 experiment[19]	 [20]	 [21]	 is	 the	most	 used	 experiment	 in	 protein-NMR.	 It	 is	frequently	used	to	characterize	protein-protein	or	ligand-protein	interactions.	To	overcome	 the	problem	of	 sensitivity,	 the	HSQC	experiment	usually	 includes	 two	INEPT	blocks;	the	first	one	transfers	the	magnetization	excited	by	the	first	90°	pulse	from	 the	 proton	 to	 the	 heteronucleus	while	 the	 second	 block	 follows	 the	 opposite	path	 to	 transfer	 the	 magnetization	 back	 to	 the	 proton.	 In	 Figure	 10,	 the	 pulse	sequence	of	a	basic	HSQC	experiment,	that	consists	of	five	main	blocks,	is	shown.		At	the	 end	of	 the	2τ	 interval	 of	 the	 first	 INEPT,	 the	proton	antiphase	magnetization	 is	generated.	 In	 the	middle	 of	 the	 2τ	 period,	 a	 180°	 pulse	 is	 applied	 on	 both	 spins	 to	refocus	the	chemical	shift	evolution.	In	the	second	step,	coherence	is	transferred	from	the	proton	to	the	bound	heteronucleus	(spin	S)	through	two	simultaneous	90°	pulses.		Then,	the	S-spin	coherence	is	frequency-labeled	during	the	period,	t1.	A	180°	pulse	on	the	proton	in	the	middle	of	t1	refocuses	the	evolution	of	heteronuclear	JHS	coupling.	In	the	 fourth	 step,	 a	 90°	 pulse	 on	 both	 spins	 transfers	 the	magnetization	 back	 to	 the	proton	as	antiphase	1H-spin	magnetization.	The	 final	spin-echo	period	converts	 this	antiphase	 term	 into	 in-phase	 proton	 magnetization,	 which	 is	 acquired	 during	 the	period,	t2[22].	
	
Figure	10	Pulse	sequence	of	a	general	HSQC	experiment		
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The	 [1H,15N]-HSQC	 experiment	 is	 the	most	 standard	 experiment	 and	 shows	 all	H-N	correlations.	These	are	mainly	the	backbone	amide	groups,	but	Trp	side-chain	Nε-Hε	groups	and	Asn/Gln	side-chain	Nδ-Hδ2/Nε-Hε2	groups	are	also	visible.	The	Arg	Nε-Hε	peaks	are	in	principle	also	visible,	but	because	the	Nε	chemical	shift	is	outside	the	region	 usually	 recorded,	 the	 peaks	 are	 folded/aliased	 (this	 essentially	 means	 that	they	 appear	 as	 negative	 peaks	 and	 the	 Nε	 chemical	 shift	 has	 to	 be	 specifically	calculated).	 If	working	at	 low	pH,	 the	Arg	Nη-Hη	and	Lys	Nζ-Hζ	groups	 can	also	be	visible,	 but	 are	 also	 folded/aliased	 (Figure	 11)[23].	 The	 spectrum	 is	 rather	 like	 a	fingerprint	and	is	usually	the	first	heteronuclear	experiment	performed	on	proteins.		
	
Figure	11	Example	of	a	[1H,15N]-HSQC	spectrum	of	a	protein;	the	characteristic	zones	of	the	spectrum	are	indicated[23].		
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Nuclear	Overhauser	Effect	(NOE)	While	 scalar	 coupling	 is	mediated	by	 electron	density	 and	provides	 information	on	the	proximity	between	the	atoms	in	the	chemical	structure,	 there	is	another	type	of	interaction	 between	 nuclear	 spins,	 which	 depends	 on	 the	 local	 magnetic	 fields	produced	by	the	magnetic	moments	of	the	spins	themselves.	The	effect	of	the	dipolar	interaction	can	be	measured	as	a	change	in	the	populations	of	the	energy	levels	of	the	coupled	spin.	This	effect	is	known	as	NOE	(Nuclear	Overhauser	Enhancement):	given	two	 dipolar	 coupled	 spins,	 I	 and	 S,	 if	 the	 equilibrium	 of	 S	 is	 perturbed,	 there	 is	 a	change	in	the	magnetization	of	I	proportional	to	a	cross-relaxation	constant	(σIS),	and	to	the	variation	of	S	from	its	equilibrium:	! !! − !!!!" = −!! !! − !!! − !!" !! − !!! 	where	IZ	and	SZ	are	the	components	of	the	magnetization	along	the	external	magnetic	field	 and	 RI	 is	 a	 self-relaxation	 constant.	 The	 efficacy	 of	 this	 polarization	 transfer	between	spins	close	in	space	(below	5-5.5Å)	is	proportional	to	1/d6	(where	d	is	the	internuclear	distance)[18]	[22].	Referring	to	Figure	12,	if	a	resonance	A	is	irradiated,	an	increase	 (positive	NOE)	 or	 decrease	 (negative	NOE)	 of	 the	 signal	 intensity	 of	 other	resonances	 is	 observed;	 for	 example,	 resonance	C,	when	 spin	C	 is	 close	 in	 space	 to	spin	A[24].	
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Figure	12	Irradiation	of	resonance	A	leads	to	a	increase	of	peak	intensity	of	the	neighboring	spin	C	(positive	NOE)	or	to	a	decrease	of	peak	intensity	(negative	NOE)[24].			
STD	experiment	(Saturation-Transfer	Difference)	The	STD	NMR	experiment	is	one	of	the	most	popular	ligand-based	techniques	for	the	study	 of	 ligand-protein	 interactions	 by	 NMR.	 The	 success	 of	 this	 technique	 is	 a	consequence	of	the	fact	that	it	is	focused	on	the	signal	of	the	ligand,	and	can	be	used	even	with	 very	 large	 proteins	 and	 even	 if	 the	 assignment	 of	 the	 resonances	 of	 the	protein	is	not	available.	It	also	allows	the	use	of	small	amounts	of	non-labeled	protein.	The	STD	NMR	experiment	 is	based	on	the	NOE	effect	and	on	the	observation	of	 the	resonance	signals	of	ligands.	Basically,	an	STD	experiment	consists	in	the	subtraction	of	a	spectrum	in	which	the	protein	 is	selectively	saturated	(on-resonance	spectrum,	obtained	by	irradiating	a	region	of	the	spectrum	that	contains	only	resonances	of	the	receptor/protein	and	not	of	 the	 ligand,	normally	between	0	ppm	and	 -1	ppm)	with	signal	 strength	 ISAT,	 from	 one	 recorded	 without	 saturation	 of	 the	 protein	 (off-resonance	spectrum),	with	signal	 intensity	 I0.	 In	 the	difference	spectrum,	 ISTD	=	 I0	–	ISAT,	only	the	signals	of	 the	 ligand/s	which	receives	the	saturation	transfer	 from	the	
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protein	(through	spin	diffusion,	NOE	effect)	remain.	This	is	because,	for	a	ligand	with	weak	affinity	(dissociation	constant,	KD,	 in	 the	range	of	10-8	M	-	10-3	M),	 there	 is	an	exchange	between	the	bound	and	the	free	state	(Figure	13)[24].	
	
Figure	13	Scheme	of	the	STD-NMR	experiment.	The	exchange	between	free	and	bound	ligand	allows	 intermolecular	 transfer	 of	 magnetization	 from	 the	 receptor	 to	 the	 bound	 small	molecule[24].		
	
The	difference	in	intensity	due	to	the	saturation	transfer	can	be	quantified	and	is	an	indication	of	the	affinity.	For	a	molecule	that	binds	to	the	receptor,	only	the	signals	of	the	protons	that	are	in	close	contact	with	the	protein	(≤	5	Å)	and	receive	transfer	of	magnetization	appear	in	the	STD	spectrum.		
Water-LOGSY	experiment	The	 water-LOGSY	 is	 another	 1D	 experiment	 based	 on	 ligand-observation	 for	detection	of	protein-ligand	interactions[25].	As	the	STD,	water-LOGSY	is	based	on	the	transfer	 of	 magnetization	 via	 intermolecular	 NOE	 and	 spin	 diffusion.	 	 In	 this	experiment,	water	molecules	are	involved	in	the	transfer	pathway.	Upon	irradiation	
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of	the	water	signal,	the	molecules	that	interact	with	water	via	water-ligand-protein	or	protein-ligand	complexes	exhibit	a	negative	NOE	with	water	while	the	molecules	that	do	not	bind	the	protein	will	have	weak	and	positive	intermolecular	NOEs	with	water	(Figure	 14A).	Therefore,	binders	and	non-binders	can	be	discriminated	 in	a	water-LOGSY	 spectrum,	 as	 they	 display	 opposite	 signs	 for	 their	 corresponding	 peaks	(Figure	14B).		
	
Figure	14	(A)	water-LOGSY	principle	and	(B)	representation	of	a	water-LOGSY	spectrum.	
	
Computational	Chemistry	
Molecular	Docking	The	 aim	 of	molecular	 docking	 protocols	 is	 the	 prediction	 of	 the	 three	 dimensional	structure	 of	 the	macromolecular	 complex	 between	 the	 protein	 and	 the	 ligand.	 The	problem	 is	 generally	 attributed	 to	 the	 optimization	 of	 a	 mathematical	 function	(scoring	function)	through	an	appropriate	algorithm.	The	scoring	functions	associate	a	value	that	estimates	the	extent	of	interaction	in	terms	of	free	energy	of	the	complex	to	a	vector	with	the	atomic	coordinates	of	protein	and	ligand.	The	number	of	degrees	of	 freedom	 of	 the	 system	 makes	 it	 unthinkable	 to	 be	 able	 to	 treat	 it	 without	introducing	simplifications.	First,	a	binding	box	is	typically	specified,	inside	which	the	
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ligand	should	remain	(this	 is	equivalent	 to	 impose	 limitations	on	the	coordinates	of	the	atoms).	In	the	second	place,	bond	lengths	and	bond	angles	are	fixed,	reducing	the	conformational	 analysis	 to	 the	 rotation	 around	 single	 bonds.	 The	 further	 degree	 of	simplification	distinguishes	between	the	following	approaches:	
• Rigid	molecular	docking:	in	addition	to	the	simplifications	set	out	above,	also	rotations	around	single	bonds	are	not	permitted,	both	for	the	protein	and	for	the	 ligand.	 Both	molecules	 are	 then	 treated	 as	 rigid	 bodies.	 The	 number	 of	degrees	of	freedom	of	the	system	are	then	reduced	to	6	(3	translational	and	3	rotational	of	the	ligand	within	the	binding	pocket).	In	this	approach,	the	choice	of	 the	 initial	 conformation	 of	 the	 ligand	 is	 crucial	 because	 it	 is	 not	 changed	during	the	docking	protocol.	
• Semi-flexible	molecular	docking:	the	treatment	of	the	protein	is	the	same	as	in	the	 rigid	 molecular	 docking.	 The	 ligand	 however,	 is	 considered	 flexible.	Currently,	 almost	 all	 algorithms	 implement	 a	 conformational	 search	 that	maintains	bond	distances	and	bond	angles	fixed	and	allow	the	variation	of	the	dihedral	 angles.	 The	 number	 of	 degrees	 of	 freedom	 then	 rises	 to	 6	 +	 Nlrb,	where	Nlrb	is	the	number	of	rotatable	bonds	of	the	ligand.	
• Flexible	molecular	 docking:	 it	 is	 the	most	 comprehensive	 approach	 and	 the	most	 computationally	 demanding.	 A	 conformational	 search	 is	 performed	 on	both	 the	 protein	 and	 the	 ligand.	 Obviously,	 these	 types	 of	 algorithm	 are	 the	last	 ones	 in	 chronological	 order	 to	 be	 exploited	 and	 have	 probably	 not	 yet	achieved	their	 full	potential.	The	 flexibility	of	 the	protein	 is	generally	 limited	to	the	side	chains	of	 the	amino	acids	of	 the	binding	site	and	 is	 treated	 in	the	same	way	as	the	ligand	or	through	the	use	of	libraries	of	rotamers.	The	free	energy	of	binding	is	given	by	the	Gibbs-Helmholtz	equation:	
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∆! = ∆! − !∆!	where	ΔG	is	the	free	energy	of	binding,	ΔH	the	entropy,	T	is	the	temperature,	and	ΔS	the	entropy.	ΔG	is	associated	with	the	binding	constant	Ki	by	the	equation:	∆! = −!"#$!! 	where	R	is	the	gas	constant.	The	scoring	function	is	a	key	element	of	the	docking,	to	estimate	 the	 affinity	 of	 the	 compound	 for	 the	 protein.	 We	 can	 divide	 the	 scoring	functions	in	three	types:	
• Empirical	 scoring	 functions:	 these	 are	 based	 on	 the	 physical-chemical	properties	of	the	system;	the	total	free	energy	is	composed	of	several	energy	terms	 corresponding	 to	 hydrogen	 bonds,	 hydrophobic	 and	 electrostatic	interactions,	entropic	effects	and	in	some	cases	to	interactions	with	metal	ions.	A	 multilinear	 regression	 is	 then	 used	 to	 optimize	 the	 coefficients	 of	 the	equation	using	a	 training	set	of	protein-ligand	complexes	 for	which	both	 the	binding	affinity	and	the	three-dimensional	structure	are	known.	
• Scoring	 functions	based	on	 force	 field:	 these	 are	 based	on	 terms	of	molecular	mechanics	of	force	field.	
• Knowledge-based	 scoring	 functions:	 these	 are	 based	 on	 the	 principle	 that	situations	 that	 are	more	 frequently	 seen	 in	 the	 three-dimensional	 structures	are	energetically	more	favored.	The	free	energy	of	the	protein-ligand	complex	is	 then	 calculated	 as	 the	 sum	 of	 the	 free	 energy	 of	 interatomic	 contacts,	derived	 from	 the	 frequency	 of	 the	 interatomic	 distances	 in	 the	 database	 of	experimentally	determined	three-dimensional	structures.	As	 a	 scoring	 function	 may	 be	 simplified,	 the	 complexity	 of	 its	 optimization	combinatorially	 grows	with	 the	number	of	degrees	of	 freedom,	 and	 this	 in	practice	often	precludes	 the	use	of	 deterministic	 algorithms	 (i.e.,	 able	 to	 ensure	 the	optimal	
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solution).	Usually,	the	research	algorithm	is	heuristic;	therefore,	it	does	not	guarantee	that	the	solution	found	is	indeed	the	best	possible	but,	on	the	other	hand,	it	is	able	to	determine	 it	 in	 a	 reasonable	 time.	 In	 our	 case,	 the	 molecular	 docking	 software	PLANTS[26]	 [27]	was	used,	which	employs	a	search	algorithm	called	ACO,	acronym	of	Ant	Colony	Optimization,	and	is	a	class	of	optimization	algorithms	initially	introduced	by	Marco	Dorigo[28]	 and	based	on	 the	observation	of	 the	behavior	of	 an	ant	 colony.	The	molecular	docking	software	AutoDock	is	based	on	another	heuristic	algorithm,	a	genetic	algorithm	that	mimics	the	process	of	natural	selection[29].		
Tanimoto	similarity	Chemical	similarity	is	one	of	the	most	important	concepts	in	chemoinformatics[30].	It	plays	an	important	role	in	the	modern	approach	to	the	prediction	of	the	properties	of	chemical	 compounds,	 in	 the	 production	 of	 chemicals	 with	 a	 predetermined	 set	 of	properties	 and,	 specifically,	 on	 the	 development	 of	 studies	 on	 the	 design	 of	 drugs	considering	large	archives	containing	structures	of	available	chemicals	(or	potentially	available).	 These	 studies	 are	 based	 on	 the	 principle	 of	 the	 similar	 properties	 of	Johnson	and	Maggiora,	 	which	states:	similar	compounds	have	similar	properties[31].	To	determine	if	two	compounds	are	similar	to	each	other	or	not	is	a	major	problem	in	chemistry.	A	simple	count	of	shared	functions	(substructures-fragments	in	common)	can	 be	 a	 measure	 of	 the	 chemical	 distance	 when	 a	 similarity	 coefficient	 is	 used.	Dictionaries	 of	 predefined	 structural	 fragments,	 such	 as	 keys	 MACCS	 of	 the	 MDL	Information	System,	are	used	to	 identify	the	functions	contained	into	a	molecule[32].	The	structural	fragments	or	functional	groups	present	in	the	molecule	are	set	on	(bit	set	 as	 1)	 and	 those	 that	 are	 absent	 are	 kept	 off	 (bit	 set	 as	 0).	 In	 this	 way,	 every	molecule	is	defined	by	a	string	containing	a	sequence	of	1	and	0	(bit	string).	Once	the	
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molecules	have	been	represented	by	such	bit	strings,	the	Tanimoto	coefficient	can	be	used	for	evaluating	the	similarity.	If	we	are	comparing	two	molecules,	A	and	B,	and	NA	is	 the	number	of	 functions	(in	bits)	 in	A,	NB	 is	 the	number	of	 features	(in	bits)	 in	B,	and	NAB	 is	 the	number	of	characteristics	 (on	bits)	common	to	both	A	 to	B,	 then	 the	coefficient	of	Tanimoto	is	simply:	
! = !!"!! + !! − !!" 	Note	 that	 the	 “off”	 bits	 do	 not	 determine	 the	 similarity.	 Compounds	 that	 have	Tanimoto	coefficient	values	>	0.85	are	generally	considered	similar	to	each	other.	A	value	of	1	does	not	necessarily	mean	that	the	molecules	are	identical.																																
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Results	and	Discussion	
	
Expression	and	characterization	of	Bcl-XL	ΔTM	For	all	the	experiments,	we	used	a	soluble	construct	of	human	Bcl-XL	without	the	last	24	 amino	 acids	 corresponding	 to	 the	 transmembrane	 domain.	 The	 protein	 was	expressed	 uniformly	 15N	 labeled	 growing	 E.	 coli	 bacteria	 in	 M9	 medium	supplemented	with	 15NH4Cl	 for	 the	 labeling	 (see	Methods	 and	Materials).	 After	 the	purification	 steps,	 to	 test	 the	 correct	 folding	 of	 the	 protein,	 the	 2D	 [1H,15N]-HSQC	spectrum	 of	 Bcl-XL	 was	 recorded	 (Figure	 15).	 The	 signals	 of	 the	 protein	 are	 well	spread	and	closely	resemble	the	deposited	[1H,15N]-resonance	assignments		(adapted	from	BMRB	18250)	confirming	the	correct	folding	of	our	construct.	
	
Figure	15	2D	[1H,15N]-HSQC	spectrum	of	150	µM	Bcl-XL	ΔTM	with	superimposed	the	[1H,15N]	resonance	assignments	adapted	from	the	deposited	BMRB	18250.	
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In	silico	and	NMR	screening	of	a	fragments	library	After	having	proved	 the	 correct	 folding	of	Bcl-XL,	 and	with	 the	 aim	 to	 find	possible	novel	 agents	 that	bind	 to	 the	 target	protein,	we	decided	 to	 select	 a	 small	 library	of	fragments	 in	the	pursue	of	possible	small	molecules	with	 low	affinity	toward	Bcl-XL	which	can	then	be	modified	to	obtain	ligands	with	higher	affinity[12].	For	this	purpose,	we	 used	 a	 library	 of	 653	 compounds	 synthesized	 in	 the	 laboratory	 of	 Professor	Zagotto	(Dipartimento	di	Scienze	del	Farmaco,	University	of	Padova,	Italy).	To	select	only	a	few	fragments	to	be	tested	experimentally,	we	first	selected	some	compounds	using	chemoinformatic	methods,	such	as	Tanimoto	similarity,	and	molecular	docking.	This	 library	 was	 first	 compared	 with	 a	 second	 library	 (from	 ChEMBL)	 of	 625	compounds	 known	 from	 the	 literature	 to	 bind	Bcl-XL,	with	 the	 aim	of	 selecting	 the	fragments	of	our	library	that	have	some	common	features	known	to	be	important	for	the	 interaction	 with	 the	 target	 protein.	 Before	 comparing	 the	 two	 libraries,	 our	compounds	were	filtered	using	the	rule	of	three[33],	a	variant	of	the	Lipinski’s	rule	of	five[34].	 The	 Lipinski’s	 rule	 of	 five	 is	 a	 simple	 algorithm	 devised	 by	 Christopher	Lipinski	in	1997	that	turns	out	to	be	very	important	for	the	design	and	development	of	drugs.	It	is	a	rule	derived	empirically	using	information	accumulated	after	decades	of	 research	 in	 the	 pharmacological	 field.	 The	 rule	 of	 three	 was	 adapted	 for	 the	construction	 of	 fragment	 libraries	 for	 lead	 generation.	 This	 rule	 suggests	 that	 a	fragment	must	have	a	molecular	weight	≤	300	Da,	a	number	of	hydrogen	bond	donors	
≤	3,	a	number	of	hydrogen	bond	acceptors	≤	3	and	a	partition	coefficient	(ClogP)	≤	3.	This	 simple	 rule	 has	 reduced	 the	 field	 of	 investigation	 decreasing	 the	 number	 of	molecules	in	which	to	look	for	possible	hits.	The	fragments	obtained	from	the	rule	of	three	were	 then	compared	with	 the	 library	of	 the	Bcl-XL	known	binding	agents	and	submitted	to	molecular	docking.		
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For	 each	 compound	 of	 both	 libraries,	 the	 functional	 groups	 were	 identified	 by	assigning	to	each	molecule	a	string	based	on	the	MACCS	coding,	and	a	fingerprint	of	each	fragment	that	identified	its	substructures.	With	these	strings	that	identify	each	molecule,	 the	 Tanimoto	 similarity	 coefficient	 (T)	 of	 our	 compounds	 with	 any	molecule	 known	 to	 interact	with	 Bcl-XL	was	 calculated.	 The	 comparison	was	made	using	 the	 fingerprints	 by	 writing	 a	 bash	 script	 based	 on	 OpenBabel.	 Usually,	compounds	are	considered	similar	if	the	value	of	the	Tanimoto	coefficient	is	greater	than	0.85.	However,	we	were	selecting	fragments	not	thought	to	interact	with	Bcl-XL	and	 also	 we	 were	 not	 looking	 for	 compounds	 too	 similar	 to	 those	 already	 known	(because	 the	 ones	 already	 known	 are	 not	 used	 as	 drugs	 for	 different	 reasons);	instead,	 we	 were	 looking	 for	 fragments	 that	 have	 common	 features,	 but	 are	substantially	different	from	the	known	Bcl-XL	binding	agents.	Indeed,	as	expected,	the	Tanimoto	 coefficient	 of	 our	molecules	 exceeded	 at	most	 the	 value	 of	 0.5,	 and	were	selected	precisely	the	fragments	with	a	T	value	greater	than	0.5.		The	same	library	of	compounds	was	subjected	to	a	semi-flexible	molecular	docking,	where	the	protein	is	maintained	rigid	while	the	ligands	are	free	to	rotate	around	the	single	 bonds	 (see	 Methods	 and	 Materials).	 For	 the	 molecular	 docking,	 the	crystallographic	structure	of	Bcl-XL	corresponding	to	the	PDB	ID	2YXJ	was	used.	Using	the	 software	 MOE,	 the	 protein	 structure	 was	 minimized	 energetically,	 the	 protons	was	 added,	 and	 the	 partial	 charges	 were	 attributed	 according	 to	 the	 force	 field	AMBER99.	 Also	 the	 compound	 library	 was	 subjected	 to	 a	 structure	 optimization	protocol,	which	consists	 in	the	energy	minimization	of	the	geometry	using	the	force	field	MMFF94,	 and	 the	assignment	of	partial	 charges.	PLANTS	 (Protein-Ligand	ANT	System)	 was	 used	 as	 software	 for	 molecular	 docking.	 It	 is	 based	 on	 a	 class	 of	stochastic	 optimization	 algorithms	 called	 ant	 colony	 optimization	 (ACO),	 and	
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CHEMSCORE	as	scoring	function	of	the	geometries	of	the	complex	formation.	Before	starting	 the	 molecular	 docking,	 both	 compounds	 with	 high	 affinity	 toward	 Bcl-XL	were	added	to	our	library,	and	other	molecules	known	not	to	bind	the	target	protein,	as	 internal	 controls	of	 the	goodness	of	 the	docking.	 For	each	 ligand,	10	conformers	with	the	best	scoring	were	returned	as	output.	The	results	can	be	considered	good	as	the	first	compounds	in	the	list	are	precisely	those	known	to	bind	Bcl-XL	(Figure	16)	while	those	with	the	lowest	scores	are	those	without	affinity	for	the	protein.	
	
Figura	 16	 Docking	 result	 with	 the	 highest	 scores,	 which	 is	 ABT-737,	 as	 expected,	 a	compound	 known	 to	 bind	 Bcl-XL	with	 nanomolar	 affinity.	 The	 compound	was	 added	 as	 an	internal	control	to	check	the	goodness	of	the	molecular	docking.	The	pose	of	the	compound	into	the	binding	pocket	closely	resembles	the	pose	that	ABT-737	has	in	the	crystallographic	structure	with	PDB	ID	2YXJ.	The	binding	surface	 is	color-coded:	hydrophobic	area	 in	green,	H-bonding	area	in	purple,	and	mild	polar	area	in	blue.	
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Using	the	Tanimoto	coefficient	and	the	molecular	docking,	the	5	fragments	reported	in	Table	2	were	selected.	 In	Figure	17,	the	lowest	energy	pose	of	fragment	Z314	is	shown,	in	which	it	is	docked	into	the	first	hydrophobic	pocket	of	Bcl-XL.		
Table	2.	Fragments	selected	using	the	molecular	docking	and	the	Tanimoto	coefficient	for	experimental	analysis.	
ID	 STRUCTURE	 MW	(Da)	
Z65	
	
266	
Z119	
	
270	
Z166	
	
295	
Z176	
	
282	
OH
O
HO
O
O
O OHOH
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O
O
OH
HO
HO
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Z314	
	
206	
	
	
Figure	17	Docking	pose	of	fragment	Z314	into	the	binding	pocket	of	Bcl-XL.	The	fragment	is	well	 docked	 into	 the	 first	 hydrophobic	 pocket.	 The	 binding	 surface	 is	 color-coded:	hydrophobic	area	in	green,	H-bonding	area	in	purple,	and	mild	polar	area	in	blue.	
	These	 5	 fragments	were	 tested	 using	 the	 Saturation	Transfer	Difference	 (STD)	 and	the	water-LOGSY	experiments,	which	are	ligand	based	NMR	experiments.	In	the	first	experiment,	 the	 aliphatic	 region	 of	 the	 spectra	 below	 0	 ppm	where	 the	 fragments	have	no	resonances	was	 irradiated.	 In	 this	way,	 the	resonances	of	 the	protein	were	saturated	 and	 in	 case	 of	 binding,	 the	 saturation	 was	 transferred	 to	 the	 ligand	
O
O
O
OH
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decreasing	the	intensity	of	its	signals.	The	STD	spectrum	is	the	difference	between	the	spectrum	 recorded	 without	 saturating	 the	 protein	 and	 the	 saturated	 one.	 An	 STD	spectrum	presents	signals	of	the	ligand	only	in	the	case	of	binding	with	the	protein.	The	 water-LOGSY	 experiment	 is	 similar	 to	 the	 STD,	 but	 instead	 of	 saturating	 the	target	protein,	the	protons	of	the	bulk	solvent	(H2O)	are	saturated.	The	saturation	is	transferred	to	the	binding	ligand	by	the	water	molecules	on	the	protein	surface.	The	spectrum	results	 in	positive	 signals	 for	non-binding	molecules	 and	negative	 signals	for	 binding	 fragments	 (see	 Methods	 and	 Materials).	 Both	 the	 STD	 and	 the	 water-LOGSY	NMR	experiment	were	recorded	in	the	presence	of	30	µM	Bcl-XL	and	900	µM	of	each	fragment	in	50	mM	phosphate	buffer	at	pH	7.4	with	150	mM	NaCl.	Fragment	Z314	was	found	to	bind	to	Bcl-XL	with	both	experiments.	In	Figure	18,	the	aromatic	region	of	the	spectra	is	shown;	the	STD	spectrum	recorded	with	a	saturation	time	of	2	s	is	indicated	in	green.			
	
Figure	18	Aromatic	region	of	the	Saturation	Transfer	Difference	(STD)	experiment	of	30	µM	of	Bcl-XL	in	the	presence	of	900	µM	of	Z314.	the	off-resonance	spectrum	is	shown	in	blue,	the	on-resonance	in	red,	and	the	STD	in	green.		
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To	verify	 the	binding	and	to	avoid	the	risk	of	 incurring	 in	a	 false	positive,	 the	same	experiment	was	carried	out	varying	the	saturation	time.	In	this	way,	only	the	signals	of	 the	 ligand	 agent	 increase	 in	 intensity	 increasing	 the	 saturation	 time,	which	does	not	happen	for	false	positives.	The	signal	of	the	DMSO	can	be	used	as	internal	control	since,	not	being	a	ligand	agent,	its	signal	remains	unchanged	increasing	the	saturation	time	(Figure	19).	
	
Figure	 19	 Saturation	Transfer	Difference	spectra	 (STD)	of	30	µM	Bcl-XL	 in	 the	presence	of	900	µM	of	the	fragment	Z314	recorded	at	increasing	saturation	times.	In	blue,	red	and,	green	the	spectra	recorded	with	a	saturation	time	of	0.5	s,	2	s,	and	3	s,	respectively,	are	shown.	The	signal	of	 the	DMSO	does	not	change	 increasing	the	saturation	time	indicating	that	 fragment	Z314	is	not	a	false	positive.		In	Figure	20,	the	water-LOGSY	spectrum	of	Bcl-XL	in	the	presence	of	fragment	Z314	is	reported;	 the	 signals	 of	 our	 compound	 are	 all	 negative	 indicating	 the	 presence	 of	binding.	 Also	 in	 this	 case,	 the	 positive	 signal	 of	 DMSO	 can	 be	 used	 as	 an	 internal	control.	
DMSO	
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Figure	 20	Water-LOGSY	 spectrum	of	 30	µM	Bcl-XL	 in	 the	presence	of	 900	µM	of	 fragment	Z314.	All	the	signals	of	the	compound	are	negative	indicating	the	presence	of	binding.			
To	 further	 confirm	 the	binding,	 a	more	 robust	 protein	based	NMR	experiment	was	also	recorded,	the	2D	[1H,15N]-HSQC	with	110	µM	Bcl-XL	in	the	presence	of	2	mM	of	our	 compound.	 From	 this	 experiment	 (Figure	 21),	 a	 chemical	 shift	 perturbation	of	the	resonances	of	some	residues	situated	in	the	hydrophobic	binding	pocket	of	Bcl-XL	can	be	appreciated.	
	
DMSO	
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Figure	21	2D	[1H,15N]-HSQC	spectra	of	110	µM	15N-Bcl-XL	recorded	in	the	absence	(red)	and	in	the	presence	(blue)	of	2	mM	of	fragment	Z314.	
	
Hit	optimization	and	molecular	docking	After	this	initial	screening,	and	after	confirming	the	binding	between	fragment	Z314	and	 Bcl-XL,	 initial	 fragment	 evolution	 studies	 were	 performed	 using	 compounds	analogous	 to	 our	 initial	 hit.	 The	 scaffold	 of	 our	 compound	 is	 a	 coumarin;	 for	 this	reason,	we	chose	14	different	molecules	with	coumarin	as	main	scaffold	 (Table	 3),	with	different	substituents	 in	different	positions,	with	the	aim	of	 identifying	a	more	potent	hit.	All	 the	14	 compounds	 in	Table	 3	were	 synthesized	 in	 the	 laboratory	of	Professor	Zagotto	(Dipartimento	di	Scienze	del	Farmaco,	University	of	Padova,	Italy).		For	each	of	 these	compounds,	 the	STD,	 the	water-LOGSY,	and	the	2D	[1H,15N]-HSQC	experiments	 were	 recorded.	 Both	 the	 STD	 and	 the	 water-LOGSY	 NMR	 experiment	were	recorded	in	the	presence	of	30	µM	of	Bcl-XL	and	900	µM	of	each	fragment	in	50	
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mM	 phosphate	 buffer	 at	 pH	 7.4	 with	 150	 mM	 NaCl.	 The	 2D	 [1H,15N]-HSQC	experiments	were	 recorded	 using	 150	µM	Bcl-XL	 in	 the	 presence	 of	 3	mM	 of	 each	molecules.	The	results	for	each	experiment	are	summarized	in	Table	3.			
Table	 3	 Compounds	 selected	 for	 their	 homology	 to	 the	 initial	 hit	 Z314,	 and	 tested	 against	Bcl-XL.	 For	 all	 the	 experiments,	 the	 sign	 “-“	means	 that	 under	 our	 experimental	 conditions	there	 is	 no	 binding.	 For	 the	 STD	 and	 water-LOGSY	 experiments,	 the	 sign	 “+”	 stands	 for	presence	of	binding.	 In	 the	2D	[1H,15N]-HSQC	experiment,	 the	symbols	+,	++,	+++,	and	++++	stand	for	an	average	chemical	shift	perturbation	CSP	<	0.02	ppm,	0.02	ppm	<	CSP <	0.03	ppm,	0.03	ppm	<	CSP <	0.06	ppm,	and	CSP >	0.06	ppm,	respectively.	
ID	 STRUCTURE	 STD	 Water-LOGSY	
[1H,15N]
-HSQC	
Z69	
	
+	 -	 +++	
Z262	
	
-	 -	 -	
Z406	
	
+	 -	 ++	
Z413	
	
+	 -	 ++	
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OO O
O
OO OH
O
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OO OH
O
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Z415	
	
-	 -	 -	
Z426	
	
+	 -	 ++	
Z585	
	
+	 -	 ++	
Z622	
	
+	 +	 +++	
Z1474	 	 +	 -	 +	
Z1486	 	 +	 -	 +	
Z1537	
	
-	 -	 -	
OO O
O
HO
O
OO OH
O
OO OH
OO
Br
OO OH
OO
OO
O
O
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Z1707	
	
-	 -	 -	
Z1777	
	
+	 +	 ++++	
	In	 Figure	 22	 and	 Figure	 23,	 the	 experiments	 for	 compound	 Z622	 and	 Z1777,	respectively,	are	reported.	The	saturation	of	the	signals	in	the	STD	spectra	was	very	weak	 for	both	 ligands,	but	with	 the	confirmation	of	 the	 interaction	 from	the	water-LOGSY	experiment	and	from	the	more	robust	2D	[1H,15N]-HSQC	experiment,	we	can	say	that,	under	our	experimental	conditions,	the	two	compounds	bind	to	Bcl-XL.	
	
Figure	 22	 STD	 spectrum	 (A)	 and	 water-LOGSY	 spectrum	 (B)	 of	 30	 µM	 of	 Bcl-XL	 in	 the	presence	of	900	µM	of	Z622.	For	both	 spectra,	 the	 signals	of	 compound	Z622	are	boxed	 in	red.	Both	experiments	suggest	the	presence	of	binding	under	our	experimental	conditions.	
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Figure	 23	 STD	 spectrum	 (A)	 and	 water-LOGSY	 spectrum	 (B)	 of	 30	 µM	 of	 Bcl-XL	 in	 the	presence	of	900	µM	of	Z1777.	For	both	spectra,	the	signals	of	compound	Z1777	are	boxed	in	red.	Both	experiments	suggest	the	presence	of	binding	under	our	experimental	conditions.		In	 addition,	 a	 2D	 [1H,15N]-HSQC	 titration	was	 performed	 for	 compounds	 Z622	 and	Z177	 that	 were	 found	 to	 be	 active	 in	 all	 the	 experiments.	 In	 Figure	 24,	 the	superposition	 of	 the	 2D	 [1H,15N]-HSQC	 spectra	 of	 150	 µM	 Bcl-XL	 alone	 and	 in	 the	presence	 of	 0.5	mM,	 1	mM,	 2	mM,	 and	 3	mM	 of	 compound	 Z1777,	 respectively,	 is	reported.	
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Figure	24	NMR	titration	of	Z1777	against	150	µM	15N-Bcl-XL		using	2D	[1H,15N]-HSQC	spectra.	The	spectrum	of	the	apo	protein	is	depicted	in	red	while	the	spectra	in	orange,	green,	purple,	and	blue	were	collected	in	the	presence	of	Z1777	in	increasing	concentrations:	0.5	mM,	1	mM,	2	mM,	and	3	mM,	respectively.	The	resonances	corresponding	to	the	most	perturbed	residues	are	boxed	in	orange.	 	From	 the	Chemical	 Shift	 Perturbation	 (CSP)	data,	 the	 average	dissociation	 constant	(Kd)	were	calculated.	A	Kd	value	of	1.45	mM	was	found	for	compound	Z622	(Figure	
25B),	and	a	Kd	value	of	950	µM	was	found	for	compound	Z1777	(Figure	25A).	 	The	chemical	 shift	 deviations	 for	 compound	 Z1777	 are	 plotted	 for	 each	 residue	 to	summarize	 the	 magnitude	 of	 the	 shift	 in	 the	 spectrum	 (Figure	 26).	 The	 residues	presenting	largest	shifts	are	concentrated	in	the	proximity	of	the	hydrophobic	pocket	of	 Bcl-XL,	 suggesting	 an	 interaction	 of	 our	 compound	 with	 the	 target	 protein	 that	resembles	 the	 interaction	 with	 the	 already	 known	 binding	 agents	 of	 Bcl-XL	 as	indicated	by	the	chemical	shift	perturbation	map	(Figure	27).			
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Figure	 25	Determination	of	Kd	of	Z1777	 (panel	A),	 and	Z622	 (panel	B)	using	 the	 chemical	shift	perturbation	 from	the	2D	[1H,15N]-HSQC	experiments.	Kd	=	(950	±	108)	µM	for	Z1777,	and	Kd	=	(1.45	±	0.25)	mM	for	Z622.			
	
Figure	 26	 Chemical	 Shift	 Perturbation	 (CSP)	 plot	 of	 the	 residues	 of	 Bcl-XL	 from	 the	 2D	[1H,15N]-HSQC	 titration	with	 compound	 Z1777.	 The	 red	 line	 corresponds	 to	 0.05	 ppm,	 the	value	above	which	the	CSP	was	considered	significant.		 			 	
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Figure	 27	Chemical	 shift	perturbation	map	consequent	 to	 the	binding	between	Bcl-	XL	 and	Z1777.	The	secondary	structure	of	Bcl-XL	is	depicted	in	red	for	the	residues	with	CSP	>	0.08	ppm,	and	in	orange	for	the	residues	with	0.05	<	CSP	<	0.08	ppm.		
At	 this	 point,	 it	would	 be	 necessary	 to	 obtain	more	 detailed	 structural	 information	about	 the	 protein-ligand	 interaction	with	 the	 aim	 of	modifying	 our	 hit	 to	 obtain	 a	compound	 (lead)	 with	 higher	 affinity	 towards	 Bcl-XL.	 Usually,	 both	 X-ray	crystallography	and	NMR	are	used	to	determine	a	high-resolution	co-structure.	This	approach	is	very	time-consuming	and,	with	small	molecules	with	low	affinity,	often	it	does	 not	 yield	 satisfactory	 results.	 	 For	 this	 reason,	 we	 decided	 to	 opt	 for	 a	bioinformatics	 approach.	 The	 molecular	 docking	 could	 be	 a	 rapid	 alternative	 to	provide	protein-ligand	structures,	even	though	this	method	suffers	from	the	problem	that	the	correct	docked	structure	has	to	be	predicted.	To	increase	the	reliability	of	the	molecular	 docking	 results,	 we	 decided	 to	 combine	 the	 advantages	 given	 by	 the	
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molecular	 modeling	 with	 the	 experimental	 information	 given	 by	 the	 NMR	experiments.	 The	 chemical	 shift	 perturbations	 information	 obtained	 from	 the	 2D	[1H,15N]-HSQC	spectra	were	used	to	guide	and	filter	the	molecular	docking	calculation	using	the	AutoDockFilter	program[35].		First,	we	ran	the	molecular	docking	using	AutoDock	as	docking	software[29],	using	the	Autodock/Vina	plug-in	for	pymol.	The	coordinates	of	the	binding	pocket	of	PDB	2YXJ	of	Bcl-XL	were	set	and	the	output	were	the	30	lowest	energy	conformations	of	Z1777	(Figure	28B).	At	this	point,	using	the	experimental	CSP	information	(Figure	28A)	we	used	 the	 AutoDockFilter	 program	 to	 filter	 the	 low	 energy	 conformation	 that	 is	 in	accordance	with	the	information	derived	from	the	NMR	experiment	(Figure	28C).	The	 docking	 pose	 obtained	 with	 AutoDockFilter	 is	 shown	 in	 Figure	 29;	 the	interaction	 is	 with	 the	 residues	 that	 present	 bigger	 chemical	 shift	 perturbations.	Specifically,	an	H-bond	interaction	is	present	that	is	fundamental	for	binding	with	Bcl-XL	and	also	a	hydrophobic	interaction	through	the	coumarin	scaffold.				
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Figure	 28	 (A)	 2D	 [1H,15N]-HSQC	 spectra	 of	 15N-Bcl-XL	 with	 increasing	 concentrations	 of	Z1777.	 The	 CSP	 information	 from	 these	 experiments	 was	 used	 to	 guide	 the	 molecular	docking.	 (B)	 All	 the	 30	 poses	 obtained	 from	 the	 docking	 with	 AutoDock.	 (C)	 The	 pose	 of	Z1777	 docked	 into	 the	 binding	 pocket	 of	 Bcl-XL	 obtained	 filtering	 the	 30	 solutions	 with	AutoDockFilter.	
	
C 
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Figure	 29	 Details	 of	 the	 interaction	 between	 Z1777	 and	 Bcl-XL	 from	 the	 co-structure	obtained	with	AutoDockFilter.						 	
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Conclusions	
The	 cellular	 homeostasis	 is	 maintained	 when	 the	 consistency	 of	 mitosis	 (cell	proliferation)	in	a	tissue	is	balanced	by	death	(apoptosis)	of	an	equivalent	number	of	cells[11].	In	physiological	conditions,	apoptosis	guarantees	the	homeostasis	of	tissues,	maintaining	 the	 number	 of	 cells	 constant,	 thanks	 to	 the	 balance	 between	 pro-	 and	anti-apoptotic	 proteins[36].	 A	 dysregulation	 in	 the	 apoptotic	 process,	 in	 particular	 a	lack	of	apoptosis,	is	a	central	point	in	the	development	of	cancer.	The	importance	of	studying	 this	process	 is	 evident	 in	order	 to	 identify	 anticancer	 therapeutics	 able	 to	interfere	 with	 the	 proteins	 responsible	 for	 this	 balance.	 The	 Bcl-2	 protein	 family	regulates	 the	 apoptotic	 process,	 and	 in	 particular	 the	 anti-apoptotic	 proteins	belonging	 to	 it	 are	 responsible	 for	 the	 resistance	 of	 cancer	 cells.	 In	 this	 study,	 we	investigated	Bcl-XL,	 one	 of	 the	 anti-apoptotic	 proteins	 belonging	 to	 this	 family,	 and	one	of	the	most	involved	in	the	process	of	programmed	cell	death,	which	makes	it	one	of	the	most	attractive	proteins	for	the	development	of	anticancer	agents.		In	the	pursue	of	binding	agents	of	Bcl-XL,	we	conducted	a	fragment-based	campaign.	Starting	from	a	library	of	more	than	600	compounds,	5	fragments	were	selected	using	computational	 techniques	 and	 tested	 using	 Nuclear	 Magnetic	 Resonance	spectroscopy	(NMR).	One	of	such	fragments	was	 found	to	weakly	bind	to	the	target	protein.	The	scaffold	of	this	compound	was	used	to	develop	14	analogues	that	were	tested	using	 ligand-based	NMR	experiments,	 such	as	Saturation	Transfer	Difference	(STD)	and	water-LOGSY,	and	 the	protein-based	NMR	experiment	2D	 [1H,15N]-HSQC.	The	compound	Z1777	was	found	to	bind	to	Bcl-XL	with	a	dissociation	constant	of	950	
µM.	 In	addition,	molecular	docking	was	performed	using	AutoDock,	 and	 the	 results	was	 guided	 and	 filtered	 through	 AutoDockFilter	 using	 the	 Chemical	 Shift	Perturbation	(CSP)	information	obtained	from	the	NMR	experiment.	In	this	way,	we	
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obtained	a	convincing	structure	of	the	complex	Bcl-XL-Z1777,	which	will	allow	us	to	make	structural	considerations	for	the	hit	to	lead	maturation.																																						 								 	
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Chapter	2	
The	cell	surface	receptor	CD44:	
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Introduction	
	 The	cell	surface	receptor	CD44,	a	type	I	transmembrane	glycoprotein,	was	first	described	in	1983[37].	This	hyaluronan-binding	protein	is	expressed	on	the	surface	of	many	cell	types[38]	[39],	where	it	is	involved	in	leukocyte	migration	to	inflamed	sites,	T	cell	 activation,	 and	 tumor	 metastasis[40]	 [41]	 [42].	 Several	 studies	 suggest	 that	 the	interactions	 between	 the	 adhesion	 of	 CD44	 with	 its	 main	 natural	 ligand,	 the	hyaluronic	acid	(HA)	are	critical	for	its	function	[38]	[43]	[44].	HA	is	a	linear	copolymer	of	repeating	N-acetyl-D-glucosamine	and	D-glucuronic	acid	units,	and	represents	one	of	the	 most	 abundant	 component	 of	 the	 extra-cellular	 matrix[45].	 There	 are	 several	isoforms	 of	 CD44[46],	 and	 this	 variability	 is	 enhanced	 by	 the	 presence	 of	 post-translational	modifications,	most	notables	 is	 its	glycosylation	(both	N-	and	O-linked	carbohydrate	 side	 chains)[47].	 Each	 of	 the	 different	 isoforms,	 however,	 is	characterized	by	a	fixed	N-terminal	domain	that	functions	as	docking	site	for	HA[48].	In	 particular,	 the	 recognition	 of	 HA	 by	 CD44	 is	 permitted	 by	 the	 presence	 in	 the	amino-terminal	region	of	about	90-amino	acids	containing	the	highly	conserved	Link	domain	(residues	32-124)	[39].		It	 has	 been	 observed	 that	 CD44	 expression	 enhances	metastatic	 behavior	 of	cancer	 cells[49]	 enabling	 	matrix	metalloproteases	 (MMPs)	 activation,	 thus	 enabling	many	 biological	 processes[50]	 [48]	 that	 result	 into	 the	 cleavage	 of	 CD44,	 and	concomitant	 cancer	 cells	 detachment	 and	 migration[39].	 	 Moreover,	 in	 Chronic	Lymphocytic	 Leukemia	 (CLL),	 CD44	 has	 been	 reported	 to	 signal	 B-cell	 survival	 by	activating	both	the	PI3K/AKT	as	well	as	the	MAPK/ERK	pro-survival	pathways,	and	by	inducing	the	expression	of	the	anti-apoptotic	protein	Mcl-1[51].	Accordingly,	Mcl-1	
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inhibitors	or	an	anti-CD44	antibody	can	revert	these	effects	and	induce	apoptosis	in	primary	CLL	cells	[52]	[53].	Hence,	 in	 recent	 years	 several	 laboratories	 have	 attempted	 to	 identify	 CD44	binding	agents	for	the	development	of	novel	therapeutics.	The	involvement	of	CD44	in	cells	migration	and	its	overexpression	on	a	wide	spectrum	of	tumor	cells,	make	this	receptor	also	a	suitable	target	for	delivery	of	chemotherapeutics	in	cancer	cells.	Most	approaches	targeting	CD44	have	either	used	antibodies	or	small	peptides	binding	to	CD44	 epitopes.	Other	 targeting	 strategies	 used	 the	 natural	 CD44	 ligand,	 hyaluronic	acid	 (HA),	 as	 a	 backbone	 or	 scaffold	 for	 drug	 attachment,	 or	 as	 both	 a	 targeting	moiety	and	delivery	agent	for	small	molecule	therapeutics[54].		Of	 these	 putative	 CD44	 interacting	 agents,	 the	 peptide	 A6,	 an	 8-amino	 acid	peptide	 (acetyl-KPSSPPEE-amino),	 has	 been	 shown	 to	 have	 anti-invasive,	 anti-migratory,	 and	 anti-angiogenic	 activities	 in	 a	 variety	 of	 in	 vitro	 and	 in	 vivo	 model	systems[55]	[56]	[57].	Recent	studies[58]	with	human	CLL	B-cell	lymphocytes	have	shown	that	 A6	 down	 modulates	 the	 expression	 of	 CD44	 and	 ZAP-70	 (a	 marker	 for	 an	aggressive	 form	of	 CLL),	 and	 inhibits	B-cell	 receptor	 (BCR)	 signaling,	 resulting	 in	 a	direct,	 dose-dependent,	 cytotoxicity	 in	 vitro.	 Currently	 the	 putative	 CD44	 binding	peptide	A6	is	in	phase	2	clinical	trial	in	patients	with	CLL	and	SLL	(Small	Lymphocytic	Lymphoma)[49]	(ClinicalTrials.gov	Identifier:	NCT02046928).		From	 structural	 data,	 however,	 one	 might	 conclude	 that	 CD44	 is	 not	particularly	‘druggable’	as	a	target	[59].	The	HABD	has	no	obvious	well-formed	or	deep	pockets	that	would	serve	as	attractive	binding	sites	for	small	molecule	inhibitors	and	is	known	to	undergo	small	but	 important	conformational	changes	upon	HA	binding	
[60].	Similarly,	the	stem	region	is	unlikely	to	possess	a	well-defined	three-dimensioned	structure	to	accommodate	a	ligand.	Nonetheless,	the	biological	relevance	of	CD44	in	
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cancer	 metastasis	 provides	 further	 impetus	 for	 the	 identification	 of	 suitable	 and	novel	CD44	binding	agents,	either	peptides	or	small	molecules.	To	this	end	we	sought	to	 first	 characterize	 the	 binding	 of	 reported	 putative	 CD44	 binding	 compounds.	Moreover,	we	 used	 an	NMR	 guided	 fragment-based	 screening	 campaign	 to	 identify	possibly	novel	agents.			 	
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Results	
	
Expression	and	characterization	of	hCD44(21-178)	and	HA8	binding	
studies	For	 all	 the	 experiments	 we	 used	 a	 soluble	 construct	 of	 human	 CD44	 from	residue	 Q21	 to	 residue	 V178,	 corresponding	 to	 the	 HA	 Binding	 Domain	 (HABD).	Uniformly	 15N	 labeled	 hCD44(21-178)	 was	 expressed	 in	 E.	 coli	 and	 purified	 as	reported	by	Banerji	et	al.[61].	The	yield	of	the	protein	was	about	14	mg	per	liter	of	M9	medium	 in	 the	 monomeric	 form.	 The	 2D	 [1H,15N]-sofast-HMQC[62]	 spectrum	 of	hCD44(21-178)	 closely	 resembles	 the	 previously	 reported	 spectrum[63]	 and	 the	deposited	[1H,15N]	resonance	assignments	(BMRB	ID	6093).	Furthermore,	we	tested	the	ability	of	our	construct	to	bind	its	natural	ligand,	Hyaluronic	Acid	(HA)[64]	[43]	[44].	Structural	studies	have	been	reported	for	the	complex	between	HA8	(Figure	30)	and	murine	 CD44	 HABD	 by	 X-ray	 crystallography[60]	 (PDB	 2JCR).	 In	 addition,	 the	 NMR	structure	of	hCD44	HABD	 in	complex	with	HA8	was	also	 reported[63],	 although	only	the	 coordinates	 of	 the	 protein	 were	 deposited	 (PDB	 1POZ).	 Hence,	 we	 prepared	 a	model	of	the	structure	of	hCD44	HABD	in	complex	with	HA8	using	SWISS-MODEL[65]	
[66]	 [67]	 [68]	 and	 the	 PDB-ID	 2JCR	 as	 template	 (Figure	 30).	 To	 test	 the	 ability	 of	 our	hCD44(21-178)	 to	 bind	 HA8,	 a	 20	 μM	 solution	 of	 15N-hCD44(21-178)	 was	 titrated	with	increasing	amounts	of	HA8	(20,	40,	60,	80,	100,	120,	140,	160,	180,	200,	and	220	μM,	respectively)	collecting	both	1D	1H	and	2D	[1H,15N]-sofast-HMQC	NMR	spectra	at	each	HA8	concentration	(Figure	31	and	32).	Binding	of	HA8	to	hCD44(21-178)	could	be	appreciated	by	chemical	shift	perturbations	 induced	in	the	1H-aliphatic	region	of	the	spectrum	of	hCD44(21-178)	(Figure	31).		
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Figure	 30	 Semitransparent	 molecular	 surface	 representation	 of	 the	 homology	 model	 of	hCD44	built	with	SWISS-MODEL	[65]	[66]	[67]	[68]	using	the	structure	of	mCD44	in	complex	with	HA8	(PDB	2JCR)	as	template.	HA8	(chemical	structure	is	reported	in	the	upper	panel)	and	the	HA	binding	pocket	are	colored	in	orange.	The	glycosylation	sites	are	highlighted	in	purple.	
	
Figura	31	1D	1H-aliphatic	spectra	of	20	μM	hCD44(21-178).	The	apo	spectrum	is	blue	while	the	spectra	recorded	in	presence	of	increasing	concentrations	of	HA8	(starting	from	20	μM	to	220	μM)	are	in	purple	to	light-blue.	
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	In	 particular,	 the	 resonances	 corresponding	 to	 δ-protons	 of	 residue	 L135	seemed	 most	 affected	 by	 the	 presence	 of	 HA8.	 Interestingly,	 L135	 is	 not	 in	 direct	contact	 with	 HA8,	 hence	 the	 observed	 perturbations	 are	 likely	 a	 results	 of	conformational	changes	 in	hCD44(21-178)	 induced	by	 ligand	binding,	 in	agreement	with	previously	reported	structural	studies[69].		
	
Figure	32	2D	[1H,15N]-sofast-HMQC	of	20	μM	hCD44(21-178)	in	the	apo	form	(blue)	and	with	a	11-fold	molar	excess	of	HA8	(orange).		 Similarly,	widespread	perturbations	were	observed	in	the	2D	[1H,15N]-sofast-HMQC	 spectrum	 of	 hCD44(21-178)	 (20	µM)	 in	 presence	 of	 HA8	 (220	µM)	 (Figure	
32),	 again	 suggestive	of	binding	and	conformational	 rearrangements	upon	complex	formation.	 Finally,	 we	 used	 Isothermal	 Titration	 Calorimetry	 (ITC)	 to	 quantify	 the	dissociation	constant	between	HA8	and	our	construct	(Figure	33).		
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Figura	33	Isothermal	Titration	Calorimetry	(ITC)	for	hCD44(21-178)	titrated	with	HA8.	The	Kd	obtained	is	24.6	μM.	The	relatively	low	enthalpy	of	binding	(ΔH=	-0.7	Kcal/mol)	is	justified	by	the	weak	binding.		 We	 obtained	 a	 Kd	 value	 of	 24.6	 µM,	 which	 is	 in	 agreement	 with	 previously	reported	 values	 in	 similar	 studies	 by	 ITC[60],	 and	 by	 SPR[59].	 These	 relatively	 low	binding	 affinities	 are	 expected	 for	 the	 E.	 coli	 expressed	 non-glycosylated	 form	 of	hCD44(21-178),	 and	 the	 relatively	 low	molecular	weight	 version	of	HA	used	 in	 the	binding	experiments.	Nonetheless,	our	data	collectively	suggested	that	our	construct	was	 properly	 folded	 and	 retained	 the	 ability	 to	 bind	 to	 small	 HA	 derived	oligosaccharides.	 As	 such,	 our	 CD44	 construct	 was	 suitable	 for	 further	 studies	 to	evaluate	the	binding	properties	of	several	putative	CD44	binding	agents.				
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Validation	of	putative	binders	of	hCD44		 Over	the	past	several	years,	a	variety	studies	reported	on	numerous	putative	CD44	binding	agents,	 ranging	 from	monoclonal	antibodies,	 to	peptides	and	 to	small	organic	molecules	(Table	4).	Surprisingly,	we	found	that	with	the	notable	exception	of	HA8	and	antibodies,	none	of	these	previously	reported	agents	bound	appreciably	to	hCD44(21-178)	as	described	below.			
Table	4	
Putative CD44 binders References and comments 
Natural Ligand  
HA8 : [GlcNAc-GlcUA]4 
[64] [43] [44] 
[63]   Kd = 24.6 µM by ITC
a 
Antibodies  
DF1485 [70] From Santa Cruz Biotechnolgy Kd << 400 nM by NMRb 
Roche  Patent Number: WO 2011095498 A1c 
Peptides  
A6 Peptide: Ac-KPSSPPEE-NH2 [70] [49] 
In phase 2 
for CLL  No direct bind  
to recombinant 
hCD44(21-178) 
by NMRd 
A5G27: H-RLVSYNGIIFFLK-NH2 [71] 
Laminin α5 
peptide 
Ac-SRPQGPFL-NH2 [72] 
From blade I 
of MMP-9 
Fragment  
Compound 3: 
 
[59] 
Reported Kd by SPR is 0.9 mM 
No appreciable binding by NMR or 
ITCe 
 aIsothermal	 Titration	 Calorimetry	 (ITC)	 data	 as	 reported	 in	 Figure	 1.	 The	 data	 are	 in	agreement	with	similar	measurements	from	ref.	[60].	bNo	Kd	was	reported	in	literature	for	this	antibody.	By	NMR	spectroscopy	with	recombinant	15N-hCD44(21-178)	we	estimated	a	Kd	value	<<	400	nM.	cThis	antibody	is	not	commercially	available.	We	tested	peptides	regions	cited	in	the	patent	as	putative	CD44	binding	elements.	However,	under	the	reported	experimental	condition,	none	of	these	peptides	bound	to	hCD44(21-178)	significantly.	dUsing	 15N-hCD44(21-178)	 at	 20	 μM	 we	 could	 not	 detect	 significant	 binding	 for	 these	peptides	when	tested	at	a	concentration	up	to	500	μM.	eIn	[1H,15N]-sofast-HMQC	correlation	spectra	with	15N-hCD44(21-178)	at	20	μM,	compound	3	did	not	 show	appreciable	 binding	up	 to	 20mM.	 In	 addition,	 the	 compound	was	not	 able	 to	significantly	displace	the	binding	of	HA8	to	CD44	at	55	mM	by	ITC	(see	text	and	supporting	information).	
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HCAM	 (DF1485),	 from	 Santa	 Cruz	 Biotechnology,	 is	 a	 mouse	 anti-CD44	monoclonal	antibody	of	about	90-95	kDa.	The	2D	[1H,15N]-sofast-HMQC	of	hCD44(21-178)	at	10	μM	is	reported	in	Figure	34	 in	absence	(blue)	and	in	presence	(magenta)	of	the	DF1485	antibody	at	1:1	stoichiometry.		
	
Figure	34	CD44	antibody	DF1485.	2D	[1H,15N]-sofast-HMQC	spectra	of	10	μM	15N-hCD44(21-178)	recorded	in	absence	(blue)	and	in	presence	(magenta)	of	10	μM	DF1485	antibody.	Due	to	 the	high	molecular	weight	 of	 the	 antibody-CD44	 complex,	 as	 a	 result	 of	 the	binding,	 the	signals	 of	 the	 protein	 are	 broadened	 beyond	 detection.	 After	 the	 addition	 of	 500	 μM	 A6	peptide	the	antibody	is	not	displaced,	corroborating	the	findings	of	panel	B	that	A6-peptide	does	not	appreciably	bind	to	hCD44(21-178).		 Complex	 formation	 was	 evident	 by	 the	 extensive	 line	 broadening	 beyond	detection,	 typical	 of	 a	 complex	 of	 large	molecular	weight	 (>	100	kDa).	 Similar	 data	were	obtained	at	5	μM	hCD44(21-178)	 	and	4	μM	DF1485	concentration,	 indicating	an	upper	 limit	 for	 the	Kd	of	 the	complex	of	∼	400	nM	(Table	 4).	A	second	antibody	
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was	 recently	 reported	 (patent	 number	 US	 20130224108	 A1),	 however	 it	 is	 not	commercially	available,	hence	could	not	be	tested.		The	most	advanced	putative	ligand	of	hCD44	is	the	A6-peptide	(Table	4),	that	is	currently	 in	phase	2	clinical	 trial	 in	patients	with	Chronic	Lymphocytic	Leukemia	(CLL)	 and	 Small	 Lymphocytic	 Lymphoma	 (SLL)[49](ClinicalTrials.gov	 Identifier:	NCT02046928).	Similar	to	what	we	reported	for	HA8	and	DF1485,	 in	Figure	35	are	shown	the	superimposed	2D	[1H,15N]-sofast-HMQC	spectra	of	15N-hCD44(21-178)	(20	mM)	in	absence	(blue)	and	in	presence	(green)	of	the	A6-peptide	(500	μM).		
	
Figure	35	2D	[1H,15N]-sofast-HMQC	spectra	of	20	μM	15N-hCD44(21-178)	 in	absence	(blue)	and	 in	 presence	 (green)	 of	 500	 μM	 A6	 peptide.	 No	 appreciable	 binding	 is	 detected	 under	those	experimental	conditions.		 The	 superposition	 revealed	 no	 significant	 changes	 in	 chemical	 shifts	 upon	titration	 of	 the	 ligand,	 suggesting	 the	 absence	 of	 appreciable	 binding	 under	 our	experimental	conditions.	The	absence	of	direct	interactions	between	A6-peptide	and	
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recombinant	 non-glycosylated	 hCD44(21-178)	 was	 also	 confirmed	 by	 ITC	 (Figure	
36).		
	
Figure	36	 Isothermal	Titration	Calorimetry	(ITC)	of	hCD44(21-178)	titrated	with	A6.	There	is	no	evidence	of	binding	in	our	experimental	condition.		 These	 results	 are	 in	 agreement	with	what	was	 found	very	 recently	by	Liu	et	
al.[73]	using	a	sensitive	Surface	Plasmon	Resonance	(SPR)	binding	assay.	Because	the	activity	of	A6	against	CD44	was	probed	in	cellular	studies	using	DF1485[70],	we	also	investigated	the	possibility	of	a	direct	interaction	between	the	antibody	and	A6.	For	these	studies	we	synthesized	a	13C	labeled	A6	peptide	by	introducing	a	13C	methyl	in	its	N-terminal	acetyl	group	(13C-A6	peptide).	Subsequently	we	recorded	2D	[1H,13C]-HSQC	 spectra	 of	 5	 μM	 13C-A6-peptide	 in	 absence	 and	 in	 presence	 of	 4	 μM	DF1485	antibody	 (Figure	 37).	 Unlike	 CD44,	 no	 signal	 broadening	 or	 chemical	 shift	perturbations	 could	 be	 detected	 for	 13C-A6	 in	 presence	 of	 DF1485.	 Hence,	 it	 is	possible	 that	 A6	 bound	 to	 CD44	 only	 when	 it	 is	 fully	 glycosylated	 and/or	 that	 it	recognized	a	CD44	region	that	is	outside	the	HA	binding	domain.		
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Figure	 37	 2D	 [1H,13C]-HSQC	 spectra	 of	 5	 μM	 13C-A6	 peptide	 in	 absence	 (green)	 and	 in	presence	(magenta)	of	4	μM	DF1485	antibody.	The	signal	of	the	13C-labeled	acetyl	methyl	of	the	 peptide	 is	 not	 perturbed	 by	 the	 presence	 of	 the	 antibody,	 indicating	 the	 absence	 of	significant	interactions	between	the	A6-peptide	and	the	antibody.		 Because	of	the	possible	therapeutic	potential	of	A6,	other	laboratories	pursued	studies	 aimed	 at	 identifying	 other	 putative	 CD44	 binding	 peptides.	Hibino	 et	 al.[71]	found	that	the	laminin	α5	synthetic	peptide	A5G27	(Table	4)	inhibits	cell	migration,	invasion	and	angiogenesis	by	binding	the	glycosaminoglycans	on	CD44.	However,	the	peptide	 presented	 limited	 solubility	 for	 binding	 studies,	 and	 again	 it	 is	 an	 unlikely	binder	for	the	non-glycosylated	version	of	hCD44.	Accordingly	from	the	2D	[1H,15N]-sofast-HMQC	spectra	of	20	μM	15N-hCD44(21-178)	with	200	μM	of	A5G27	there	was	no	evidence	of	binding.	
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Based	 on	 evidences	 related	 to	 the	 interactions	 between	 the	 Matrix	Metalloproteinase-9	 (MMP-9)	 and	 CD44[74]	 [75]	 [76],	 Dufour	 et	 al.[72]	 suggested	 that	MMP-9	 could	 be	 involved	 in	 a	 heterodimer	 formation	with	 CD44	 and	 in	 particular	that	 the	 interactions	 could	 take	 place	 between	 CD44	 and	 an	 8-amino	 acid	 peptide	(SRPQGPFL)	constituting	the	blade	I	of	the	PEX	domain	of	MMP-9.	This	peptide	was	purchased	 acetylated	 at	 the	N-terminus	 and	 amidated	 at	 the	 C-terminus	 (Table	 4)	and	 was	 tested	 at	 a	 concentration	 of	 400	 μM	 against	 20	 μM	 15N-hCD44(21-178).	However,	 also	 in	 this	 case,	 under	 these	 experimental	 conditions,	 the	 2D	 [1H,15N]-sofast-HMQC	 spectra	 of	 hCD44(21-178)	 indicated	 no	 significant	 binding	 of	 this	peptide	to	our	CD44	construct.		Recently	Liu	et	al.[59]	 performed	 a	 fragment	 screening	 of	 the	Maybridge	 Ro3	Diversity	Library	with	the	goal	of	identifying	initial	fragment	hits.	The	authors	of	this	work	 screened	 the	 fragments	using	 immobilized	CD44	HABD	 in	 a	 SPR	based	assay.	The	most	potent	fragment	reported	(compound	3	in	Table	4)	was	crystallized	(PDB	4MRG).	To	validate	 the	binding	of	 this	 fragment,	 	 initially	we	recorded	2D	 [1H,15N]-sofast-HMQC	spectra	of	20	μM	15N-hCD44(21-178)	(Figure	38)	in	absence	(blue)	and	in	presence	(red)	of	2	mM	of	compound	3.	Because	under	these	conditions	there	was	no	evidence	of	binding,	we	increased	the	concentration	of	the	fragment	up	to	20	mM.	At	this	concentration	we	detected	large	perturbations	in	the	chemical	shift	of	the	15N-hCD44(21-178)	resonances,	but	after	 further	 investigation	we	noticed	 that	 the	high	concentration	of	compound	3	had	also	increased	the	pH	of	the	solution	from	the	value	of	6.7	to	about	8.	After	bringing	the	pH	to	the	initial	value	of	6.7,	the	signals	on	the	2D	[1H,15N]-sofast-HMQC	 spectrum	 of	 15N-hCD44(21-178)	 in	 presence	 of	 20	 mM	compound	3	matched	the	spectrum	of	the	apo	form,	indicating	the	absence	of	binding	in	these	experimental	conditions	(Figure	39).	
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Figure	 38	 Compound	 3[59].	 2D	 [1H,15N]-sofast-HMQC	 spectra	 of	 20	 μM	 15N-hCD44(21-178)	recorded	 in	 absence	 (blue)	 and	 in	 presence	 (red)	 of	 2	mM	 compound	 3	 [59].	 No	 binding	 is	detected.	 The	 absence	 of	 significant	 interactions	 is	 confirmed	 by	 Isothermal	 Titration	Calorimetry	 in	 a	 competition	 assay	 in	 which	 hCD44(21-178)	 is	 incubated	 with	 a	 750-fold	molar	excess	of	compound	3	and	subsequently	the	binding	of	HA8	is	probed.	The	Kd	detected	for	HA8	under	this	condition	was	37.5	μM	with	a	ΔH=	-0.83	Kcal/mol,	hence	not	significantly	different	than	the	binding	of	HA8	to	hCD44(21-178)	in	absence	of	compound	3	(Figure	40).		 	In	 addition,	we	 performed	 a	 displacement	 assay	 using	 ITC.	 The	 dissociation	constant	 between	 HA8	 and	 hCD44(21-178)	 was	 determined	 in	 absence	 and	 in	presence	of	a	750-fold	molar	excess	of	compound	3.	The	Kd	detected	 in	presence	of	such	large	excess	of	compound	3	was	37.5	μM	(Figure	40),	hence	similar	to	the	value	obtained	in	absence	of	the	fragment	(Figure	33),	suggesting	that	the	affinity	of	HA8	for	hCD44(21-178)	was	not	significantly	affected	by	the	presence	of	compound	3.	
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Figure	39	2D	[1H,15N]-sofastHMQC	NMR	spectra	of	20	µM	15N-hCD44(21-178)	in	its	apo	form	(blue),	in	presence	(red)	of	20	mM	of	compound	3[59]	with	the	pH	increase	at	about	8,	and	in	presence	 (green)	 of	 20	 mM	 of	 compound	 3[59]	 at	 the	 correct	 pH.	 At	 the	 pH	 of	 6.7	 (green	spectrum)	there	are	no	evidences	of	binding.	
	
Figure	40	 Isothermal	Titration	Calorimetry	(ITC)	of	hCD44(21-178)	in	presence	of	750-fold	molar	excess,	titrated	with	HA8.	The	Kd	of	37.5	µM	is	not	significantly	different	than	the	Kd	in	absence	of	the	compound	3,	suggesting	that	this	fragment	not	significantly	compete	with	HA8.	
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Fragment	based	ligand	discovery	(FBLD)	by	NMR	In	 the	 pursue	 of	 possible	 novel	 agents	 that	 bind	 to	 CD44	 we	 performed	 a	fragment	screening	campaign	using	1D	1H-aliphatic	and	2D	[1H,15N]-sofast-HMQC	of	
15N-hCD44(21-178)	 as	 detection	 methods[77].	 Hence	 we	 tested	 a	 library	 of	 500	fragments	 from	 Maybridge	 (Fisher	 Scientific).	 To	 maximize	 the	 sensitivity	 of	 the	binding	assay,	we	used	15N-hCD44(21-178)	at	20	μM	while	each	fragment	was	tested	at	400	μM.	To	reduce	the	number	of	samples,	 fragments	were	tested	in	pools	of	10,	and	mixtures	 containing	hits	were	 further	deconvoluted.	Hence,	 of	 the	50	mixtures	tested	only	2	mixtures	presented	 significant	 chemical	 shift	perturbation	 in	both	1D	
1H-aliphatic	 and	 2D	 [1H,15N]-sofast-HMQC	 spectra.	 Further	 deconvolutions	 of	 these	mixtures	were	accomplished	by	testing	individual	compounds	at	400	μM	against	20	μM	15N-hCD44(21-178).	Of	 these	 resulting	20	samples,	 two	structurally	 related	hits	produced	significant	chemical	shift	perturbations	in	both	1D	and	2D	NMR	spectra	of	
15N-hCD44(21-178)	(Figure	41).		
									 		
Figure	41	The	two	initial	hits	came	from	the	500	fragment	screening	(Maybridge).			 Initial	 fragment	 evolution	 studies	 were	 performed	 using	 commercially	available	analogues	of	 the	 two	hits	 (Table	 5).	These	studies	 resulted	 in	a	validated	hit,	compound	131B6	(Figure	42).	Interestingly,	the	perturbations	induced	by	131B6	in	the	1D	1H-aliphatic	NMR	spectrum	of	hCD44(21-178)	(Figure	42)	closely	resemble	the	perturbations	induced	by	HA8	as	reported	in	Figure	31.			
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Table	5	Reported	fragments	tested	against	hCD44(21-178),	grouped	according	to	structural	homology	 in	 thiazoles,	 thiophenes	 and	 furans.	 Rank	 ordering	 according	 to	 the	 following	criteria:	+++,	when	shifts	of	HD1	L135,	and	HD2	L135	peaks	are	larger	than	7	Hz;	++,	when	shifts	of	HD1	L135,	and	HD2	L135	peaks	are	 in	between	3	Hz	and	7	Hz;	when	shift	of	HD1	L135,	 and	HD2	L135	peaks	 smaller	 than	3	Hz;	 -,	 no	 shift	 of	 the	peaks	HD1	L135,	 and	HD2	L135.	All	the	shifts	refer	to	the	chemical	shift	difference	to	the	apo	for	spectrum.	
THIAZOLES	
	
ID	
	 R1	 R2	 R3	 R4	 R5	
Ranking	
by	NMR	131B5	 	 -H	 -H	 	 -H	 -	131B6	 -H	 	 -H	 -H	 -H	 +++	131B7	 -H	 	 -H	 -CH3	 -H	 -	131B8	 	 -H	 	 -H	 -H	 -	131B9	 -H	 	 -H	 -CH3	 -H	 -	131B10	 -CH3	 -CH3	 -H	 -H	 	 -	131B11	 -H	 	 -H	 -H	 	 -	131B12	 -H	 -H	 -H	 -H	 	 +	131C1	 -H	 -H	 -H	 	 -H	 ++	131C2	 -H	 	 -H	 -H	 -H	 ++		
THIOPHENES	
	
ID	
	 R1	 R2	 R3	 R4	 R5	
Ranking	
by	NMR	131C3	 	 	 -H	 -H	 -	131C4	 	 	 -H	 -H	 -	131C5	 -CH3	 -H	 	 	 -	
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Tabella	5.	Continued	
	
THIOPHENES	
	
ID	
	 R1	 R2	 R3	 R4	 R5	
Ranking	
by	NMR	
131C6	 -H	 -H	 	 	 -	131C7	 -CH3	 -H	 	 	 +	131C8	 -H	 -H	 	 	 ++	131C9	 	 	 -H	 -H	 -	131C10	 -Cl	 -H	 	 -H	 -	131C11	 	 	 -H	 -H	 -	131C12	 	 -H	 	 -H	 -H		 -	
FURANS	
	ID	 R1	 R2	 R3	 Ranking	by	NMR	131D1	 	 -H	 	 -	131D2	 	 	 -	131D3	 	 	 -	
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Figure	 42	 NMR	 titration	 of	 131B6	 (structure	 on	 the	 upper	 panel)	 against	 20	 μM	 of	 15N-hCD44(21-178)	using	1D	1H-aliphatic	spectra.	The	spectra	of	the	apo	protein	are	depicted	in	blue,	while	the	spectra	 in	purple	to	 light-blue	were	collected	 in	presence	of	 the	fragment	 in	increasing	 concentration	 starting	 from	 1	 mM	 to	 15	 mM	 respectively.	 The	 resonances	corresponding	to	the	most	perturbed	residues	are	labeled.		 However,	 chemical	 shift	 perturbations	 in	 2D	 [1H,15N]-sofast-HMQC	 spectrum	(Figure	 43),	 indicated	 that	only	 a	distinct	 subset	of	 resonances	were	perturbed	by	the	ligand.	Intriguingly,	these	changes	map	in	a	region	of	the	structure	of	hCD44(21-178)	that	is	opposite	to	the	reported	HA8	binding	site	(Figure	44).	The	dissociation	constant	calculated	using	the	chemical	shift	perturbation	from	the	2D	[1H,15N]-sofast-HMQC	 spectra	 results	 in	 a	 Kd	 of	 7.43	mM	 (Figure	 45),	 hence	 in	 the	 same	 affinity	range	of	the	fragments	previously	reported[59].	Further	evaluations	of	the	binding	of	131D6	 to	 CD44	 where	 enabled	 by	 measurements	 of	 intermolecular	 NOEs	 (Figure	
46).		 			
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Figure	 43	 NMR	 titration	 of	 131B6	 against	 20	 μM	 of	 15N-hCD44(21-178)	 using	 2D	 15N-sofasHMQC	spectra.	The	spectra	of	the	apo	protein	are	depicted	in	blue,	while	the	spectra	in	purple	 to	 light-blue	were	 collected	 in	presence	of	 the	 fragment	 in	 increasing	 concentration	starting	 from	 1	 mM	 to	 15	 mM	 respectively.	 The	 resonances	 corresponding	 to	 the	 most	perturbed	residues	are	labeled.		 Hence,	2D	[1H,	 1H]	NOESY	spectra	were	recorded	with	100	μM	of	hCD44(21-178)	in	absence	(blue)	and	in	presence	(red)	of	500	μM	of	131B6.	In	the	spectrum	of	the	 complex,	 we	 could	 clearly	 observe	 in	 the	 aromatic	 region	 of	 the	 spectra,	 the	presence	of	a	cross-peak	that	connected	the	resonances	of	 the	proton	of	 the	 thiazol	(131B6)	with	the	resonances	of	the	δ-protons	of	the	leucine	135	in	hCD44(21-178),	suggesting	a	spatial	proximity	of	the	compound	to	this	aminoacid	(<	5	Å).	However,	in	a	 subsequent	 NMR	 displacement	 assay	 the	 presence	 of	 131B6	 did	 not	 prevent	 the	binding	of	HA8,	suggesting	that	under	these	conditions,	these	two	binding	events	can	exist	 simultaneously	 (Figure	 47A	 and	 47B).	Nonetheless,	 the	 screening	 revealed	a	
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possible	binding	pocket	on	the	surface	of	CD44	that	may	be	‘druggable’	and	that	may	have	functional	implications	in	cell.		
	
Figure	 44	 Semitransparent	 molecular	 surface	 representation	 of	 the	 homology	 model	 of	hCD44	built	with	SWISS-MODEL	[65]	[66]	[67]	[68]	using	the	structure	of	mCD44	in	complex	with	HA8	(PDB	2JCR)	as	template.	The	HA8	binding	pocket	is	depicted	in	orange	while	in	purple	are	highlighted	 the	 putative	 glycosylation	 sites.	 The	 Chemical	 Shift	 Perturbations	 induced	 by	131B6	are	mapped	on	the	secondary	structure	(ribbon):	∆!	>	0.14	ppm	in	green;	∆!	<	0.14	ppm	in	light	green.	The	most	perturbed	residues	are	labeled	and	localized	in	a	putative	back	pocket	opposite	from	the	HA8	binding	pocket.	The	red	square	indicates	the	portion	of	hCD44	with	sequence	homology	with	A6	peptide.	
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Figure	45	Determination	of	Kd	of	131B6	using	the	chemical	shift	perturbation	titrations	from	the	2D	[1H,15N]-sofasHMQC	experiments;	Kd	=	7.43	mM)			
	
Figure	46	2D	[1H,1H]-NOESY	NMR	spectra	of	100	µM	hCD44(21-178)	in	absence	(blue)	and	in	 presence	 (red)	 of	 500	 µM	 of	 compound	 131B6.	 In	 green	 is	 depicted	 the	 correlation	between	 the	 proton	 of	 the	 thiazole	 (compound	 131B6)	 and	 probably	 the	 β-protons	 of	 the	leucine	135	of	hCD44(21-178).	
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Figure	47	 (A)	In	blue	20	µM	15N-hCD44(21-178)	in	its	apo	form.	In	orange	the	spectrum	of	the	protein	in	presence	of	80	µM	HA8,	and	in	red	the	spectrum	after	the	addition	of	15	mM	of	the	 compound	 131B6.	 (B)	 In	 blue	 20	 µM	 15N-hCD44(21-178)	 in	 its	 apo	 form.	 In	 red	 the	spectrum	 of	 the	 protein	 in	 presence	 of	 15	mM	 of	 the	 compound131B6,	 and	 in	 orange	 the	spectrum	after	the	addition	of	8=60	µM	HA8.					 	
hCD44 
hCD44 + HA8 
hCD44 + HA8 + 131B6 
hCD44 
hCD44 + 131B6 
hCD44 + 131B6 + HA8  	
A 
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Methods	and	Materials	
	
Protein	expression	and	purification	The	human	CD44	HA	Binding	Domain	(HABD)	residues	21-178	was	expressed	in	Escherichia	Coli	and	purified	from	insoluble	inclusion	body	as	described	previously	
[61].	The	cDNA	of	hCD44(21-178)	was	cloned	into	the	vector	pET19b	and	transformed	into	 E.	 coli	 strain	 BL21(DE3)	 gold	 pLysS	 (Novagen).	 The	 overexpression	 of	 the	protein	was	obtained	growing	the	transformed	cells	in	LB	medium	at	37°C	with	100	μg/L	of	ampicillin	until	reaching	an	OD600	of	0.6	followed	by	induction	with	0.4	mM	IPTG.	 After	 OVT	 incubation	 at	 20°C,	 cells	 were	 harvested	 by	 centrifugation.	 The	inclusion	body	was	isolated	from	the	pellet	and	solubilized	in	8	M	urea	in	presence	of	1mM	 dithiothreitol	 (DTT)	 at	 4°C	 OVT.	 The	 denatured	 recombinant	 hCD44(21-178)	was	 subsequently	 refolded	 dropping	 the	 supernatant	 solution	 at	 600	 μL/h	 using	 a	syringe	pump	by	200-fold	dilution	into	buffer	containing	250	mM	L-Arginine,	100	mM	tris-HCl	pH	=	8,	2	mM	reduced	glutathione	and	1	mM	oxidized	glutathione.	After	48h	at	4°C	stirring,	the	solution	was	ultrafiltrated	through	Amicon	YM10	membranes.	The	monomeric	 protein	 was	 purified	 through	 size	 exclusion	 chromatography	 using	 a	HiLoad	26/60	Superdex	75	prep	grade	column.	For	the	expression	of	the	15N-labeled	protein	used	for	all	heteronuclear	NMR	experiments,	the	procedure	was	the	same,	but	the	bacteria	were	grown	in	M9	minimal	medium	supplemented	with	trace	elements,	0.09%v/v	glycerol	and	0.5	g/	L	15NH4Cl	for	the	labeling.		
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	Reagents	HA8	was	 purchased	 from	 Iduron	 (UK).	 The	 antibody	 DF1485	was	 from	 Santa	 Cruz	Biotechnology	 (Dallas,	 TX).	 Compound	 3	 [59]	 was	 obtained	 from	 Matrix	 Scientific	(Columbia,	 SC,	 USA).	 The	 peptides	 A6	 (Ac-KPSSPPEE-NH2),	 A5G27	 (H-RLVSYNGIIFFLK-NH2),	the	peptide	from	the	blade	I	of	the	PEX	domain	of	MMP-9	(Ac-SRPQGPFL-NH2),	 the	 three	peptides	 from	 the	 light	 chain	of	 the	Hoffmann-La	Roche	antibody	 (Ac-SRYWMS-NH2,	 Ac-EVNPDSTSINYTPSLKD-NH2,	 and	 Ac-PNYYGSRYHYYAMDY-NH2),	 and	 the	 three	 from	 the	 heavy	 chain	 (Ac-RASQDINNYL-NH2,	Ac-YTSRLHS-NH2,	and	Ac-QQGSTLPFT-NH2)	were	purchased	from	Innopep	(San	Diego,	 CA).	 13C-A6	 peptide	 was	 synthesized	 in	 our	 laboratory.	 131B6	 and	 all	 the	compounds	in	Table	5	were	purchased	from	Hit2Lead	ChemBridge	Corporation	(San	Diego,	 CA)	 except	 for	 compound	 131C1	 from	 Maybridge	 (Fisher	 Scientific)	 and	compound	131B12	from	Acros	Organics.		
13C-A6	peptide	synthesis	
13C-A6	peptide	was	synthesized	using	a	 fmoc	solid-phase	synthesis	using	 the	Rink	amide	resin.	For	the	coupling	reaction	each	amino	acid	was	dissolved	into	5	mL	of	 dry	 DMF	 containing	 6	 equivalents	 of	 Oxima	 pure,	 DIC	 and	 DIAE.	 Each	 coupling	reaction	was	 carried	 shaking	 the	 resin	 for	3	hours.	After	 the	 reaction	 the	 resin	has	been	 washed	 3	 times	 with	 8	 mL	 DMF	 followed	 by	 3	 washings	 with	 DCM	 and	 3	washings	with	DMF.	 The	 deprotection	 of	 the	 terminal	 amino	 acid	was	 achieved	 by	adding	to	the	resin-bound	peptide	a	20%	piperidine	solution	in	DMF	(1	mL	and	4	mL	respectively)	 for	40	minutes	 twice.	After	 the	 last	coupling	step,	 the	N-terminus	was	acetylated	with	 5	mL	 of	 dry	 DMF	 solution	 containing	 0.05	 equivalents	 of	 DMAP,	 3	equivalents	 of	 DIPEA	 and	 2	 equivalents	 of	 13CH3COCl	 (Cambridge	 Isotope	
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Laboratories,	Inc.).	The	cleavage	from	the	resin	and	the	removal	of	all	the	side	chains	protecting	groups	was	performed	by	shaking	at	RT	with	a	cleavage	cocktail	composed	by	 94%	 TFA,	 2%	 phenol,	 2%	 TIPS,	 and	 2%	 of	 water	 for	 5.5	 hours.	 TFA	 was	subsequently	 removed	 under	 reduced	 pressure	 using	 a	 rota-vapor	 and	 the	 peptide	was	subjected	to	few	cycles	of	precipitation	in	diethyl	ether	and	centrifugation	before	OVT	drying	in	high	vacuum.	The	peptide	was	purified	by	a	HPLC	Breeze	system	from	Waters	Co.	using	preparative	reverse	phase	column	to	get	a	purity	level	>	95%	.	The	final	peptide	was	characterized	by	NMR	and	MALDI-TOF	spectrometry.	
	
Isothermal	Titration	Calorimetry	(ITC)	The	 ITC	 measurements	 were	 performed	 with	 a	 ITC200	 calorimeter	 from	Microcal	 (Northampton,	 MA,	 USA)	 at	 23°C.	 For	 the	 direct	 experiments,	 hCD44	 (73	μM)	was	 titrated	with	 a	 solution	 containing	 1.6	mM	HA8	 (Figure	 33)	 or	 1	mM	A6	peptide	 (Figure	 36).	 For	 the	 competition	 assay	 (Figure	 40)	 the	 protein	 was	incubated	with	a	55	mM	solution	of	compound	3	and	then	titrated	with	a	solution	of	1.6	mM	HA8.	All	experiments	were	conducted	in	buffer	containing	50	mM	phosphate,	150	mM	NaCl	 at	 pH	=	 6.7	 in	 presence	 of	 5%	DMSO.	 The	 data	were	 analyzed	 using	Origin	software	provided	by	Microcal.		
	
NMR	Spectroscopy	All	 the	 NMR	 spectra	 were	 acquired	 on	 a	 600	 or	 a	 700	MHz	 Bruker	 Avance	spectrometers	equipped	with	TCI	cryoprobes	and	z-shielded	gradient	coils.	The	data	were	 processed	 and	 analyzed	 using	TOPSPIN	2.1	 (Bruker	Biospin,	MA)	 and	 Sparky	3.1	(University	of	California,	San	Francisco,	CA).	In	general,	1D	1H	experiments	were	
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acquired	using	128	 scans	with	2048	 complex	data	points,	 2D	 [1H,15N]-sofast-HMQC	experiments	using	48	scans	with	2048	and	128	complex	data	points	in	the	1H	and	15N	dimensions,	respectively,	and	the	2D	[1H,13C]-HSQC	using	64	scans	with	4096	and	128	complex	points	in	the	1H	and	13C	dimensions,	respectively.	All	samples	were	acquired	at	300	K	in	buffer	containing	50	mM	phosphate,	150	mM	NaCl,	and	0.02%	NaN3,	pH	=	6.7.	The	2D	[1H,1H]-NOESY	NMR	spectra	were	recorded	using	72	scans	with	2048	and	256	complex	data	points	 in	 the	direct	and	 indirect	dimensions,	respectively,	with	a	NOE	mixing	 time	 of	 0.2	 seconds.	 The	 Saturation	Transfer	Difference	 (STD)	NMR	 spectra	were	recorded	using	128	scans	and	saturating	 for	2	seconds	at	 -0.28	ppm	or	at	 -10	ppm	for	the	reference	spectra.	The	 dissociation	 constant	 (Kd)	 was	 calculated	monitoring	 the	 chemical	 shift	perturbations	 in	 the	2D	 [1H,15N]-sofast-HMQC	spectra	of	hCD44	(20	μM)	due	 to	 the	presence	of	increasing	concentrations	of	compound	131B6	(	1,	2,	3,	5,	7,	9,	11,	13,	and	15mM).	 The	weight	 average	 perturbations	 induced	 on	 backbone	 amide	 resonances	corresponding	 to	 residues	 D134,	 I145,	 I147	 and	 G159	 were	 determined	 using	 the	following	equation:	[78]	
∆! = (∆ !!! )! + (0.17 ∗ (∆ !)!!" !	Subsequently,	 Kd	 values	 were	 obtained	 by	 fitting	 these	 averaged	 chemical	 shift	perturbation	data	into	the	following	equation:	[79]	[80]	
∆!!"# = ∆!!"# !! + ! ! + ! ! − !! + ! ! + ! ! ! − 4 ! ! ! !2 ! ! 	where	∆!!"#	is	 the	 chemical	 shift	 perturbation	 value	 observed	 at	 each	 point	 of	 the	titration,	∆!!"#	is	the	maximum	chemical	shift	change	of	the	fully	complexed	protein,	and	 ! !	and	   !	are	the	total	concentrations	of	compound	and	protein.	
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Screening	by	NMR	The	 Maybridge	 library	 of	 500	 fragments	 was	 assembled	 in	 50	 mixtures	containing	 10	 fragments	 each	 in	 d6-DMSO.	 1D	 1H	 and	 2D	 [1H,15N]-sofast-HMQC	experiments	were	recorded	for	each	mixture	at	the	final	concentration	of	4	mM	(400	μM	 individual	 fragment	 concentration)	 against	 20	 μM	 15N-hCD44(21-178).	 The	spectra	were	recorded	in	50	mM	phosphate	buffer	pH	6.7,	150	mM	NaCl	and	0.02%	NaN3	 with	 a	 2%	 of	 d6-DMSO.	 The	 hit	 mixtures	 were	 subsequently	 deconvoluted	testing	each	fragment	individually	in	the	same	experimental	conditions.	For	the	HTS	by	 NMR	 of	 combinatorial	 libraries	 approach	 [81]	 was	 tested	 a	 four-position	combinatorial	library	(Ac-XXXX-NH2)	using	19	amino	acids	(all	the	natural	amino	acid	except	 for	 cysteine)	 as	 building	 blocks.	 In	 this	 way,	 76	 (19×4)	 mixtures	 each	containing	6,859	(19×19×19)	 individual	peptides	with	one	amino	acid	 fixed	at	one	position	 were	 synthesized	 and	 tested.	 Hence,	 we	 were	 able	 to	 test	 130,321	combinations	of	natural	amino	acid	(19×19×19×19)	just	by	synthesizing	and	testing	76	mixtures.	With	the	same	approach,	we	tested	a	tri-peptide	library	assembled	using	46	 natural	 and	 non-natural	 amino	 acid	 as	 building	 blocks	 (Pepscan	 Presto	 BV,	Lelystad,	The	Netherlands)	maintaining	one	amino	acid	fixed	at	the	first	position.	In	this	way	we	tested	2,116	peptides	(1×46×46)	just	testing	1	mixture.															
	 86	
			 	
	 87	
Discussion	
	 CD44,	via	its	interactions	with	its	ligand,	the	hyaluronic	acid,	[38]	[43]	[44]	(Figure	
30),	plays	an	important	role	in	tumor	cell	migration	and	tumor	metastasis[42]	and	as	such	 it	 is	 expressed	 on	 the	 surface	 of	 several	 types	 of	 tumors	 [38].	 Despite	 its	demonstrated	relevance	as	viable	drug	target	in	oncology,	further	assessments	on	the	biological	 role	 of	 CD44	 in	 the	 onset	 and	 progression	 of	 cancer	 is	 hampered	 by	 the	availability	 of	 suitable	 pharmacological	 tools.	 CD44	 indeed	 is	 known	 to	 be	 not	 an	easily	‘druggable’	target	[59],	due	to	the	absence	of	a	clear	well-defined	ligand	binding	pocket	 on	 its	 surface	 (Figure	 30).	 In	 addition,	 there	 are	 several	 post-translational	modifications	that	occur	in	cell,	mostly	glycosylation,	that	are	critical	for	the	activity	of	 CD44	 [47].	 However,	 the	 exact	 glycosylation	 state	 of	 the	 protein	 cannot	 be	 easily	determined	and	reproduced	in	a	test	tube.	Nonetheless,	the	recombinant	form	of	the	HA	binding	domain	of	CD44,	retaining	some	of	its	binding	affinity	for	HA,	may	provide	a	valid	platform	onto	which	to	attempt	to	derive	CD44	binding	agents.	Therefore	we	expressed	the	hCD44(21-178)	as	it	was	reported[43]	 [61]	by	using	that	such	construct	which	possesses	a	proper	folding	for	binding	HA.	Accordingly,	we	demonstrated	the	construct’s	 ability	 to	 bind	 HA8	 using	 both	 solution	 nuclear	 magnetic	 resonance	spectrometry	(NMR)	(Figure	31	and	32)	and	isothermal	titration	calorimetry	(ITC)	techniques	 (Figure	 33).	However	 and	 surprisingly,	when	 subsequently	we	 tried	 to	validate	the	binding	of	the	other	reported	putative	ligands	of	CD44	(Table	4),	these	resulted	 inactive	under	our	 experimental	 conditions,	with	 the	 sole	 exception	of	 the	antibody	 DF1485	 (Figure	 34).	 The	 results	 for	 these	 activities	 are	 summarized	 in	
Table	4.	Several	possible	causes	may	be	attributable	to	the	lack	of	binding	for	these	agents	 to	 CD44.	 For	 example,	 the	 peptide	 A5G27	 has	 a	 fairly	 low	 solubility	 in	 our	
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conditions	it	is	also	known	to	bind	the	glycosaminoglycans	on	CD44[71].	We	could	not	test	the	antibody	patented	by	Hoffman-La	Roche	and	the	University	of	Miami	(Patent	number	US	20130224108	A1)	because	it	is	not	commercially	available,	but	based	on	the	information	disclosed	in	the	patent,	we	could	select	and	test	six	peptides	of	which	three	 belongs	 at	 the	 heavy	 chain	 of	 the	 antibody,	 and	 the	 other	 three	 to	 the	 light	chain.	 Unfortunately,	 also	 all	 these	 peptides	 tested	 in	 isolation	 didn’t	 seem	 to	 bind	significantly	 the	 protein	 (see	 Methods	 and	 Materials).	 Another	 interesting	 peptide	was	reported	 in	 literature	 [72]	based	on	the	 interactions	between	CD44	and	the	PEX	domain	of	MMP-9	(Table	4).	Nonetheless,	as	mentioned,	also	this	peptide	under	our	experimental	 conditions	 didn’t	 show	 significant	 binding	 to	 CD44.	 Next,	we	 focused	our	 studies	 on	 the	 binding	 properties	 of	 the	 A6	 peptide	 given	 that	 it	 is	 in	 phase	 2	clinical	 trials	 for	 CLL	 and	 SLL	 patients[49](ClinicalTrials.gov	 Identifier:	NCT02046928).	 The	 detailed	mechanism	 of	 action	 of	 A6	 has	 not	 been	 defined,	 but	studies	 on	metastatic	 disease	 suggested	 that	 it	 functions	 through	 a	 CD44-mediated	pathway[70].	 While	 cellular	 studies	 indicated	 a	 possible	 direct	 interaction	 between	CD44	 and	 A6,	 we	 could	 not	 observe	 any	 significant	 binding	 of	 A6	 to	 15N-labeled	sample	of	hCD44(21-178)	 in	2D	[1H,15N]-sofast-HMQC	(Figure	35)	and	ITC	(Figure	
36)	experiments.	However	and	intriguingly,	the	amino	acid	sequence	of	A6	(Table	4)	exhibits	marked	homology	with	a	linear	sequence	within	CD44	(120-NASAPPEE-127)	(Figure	 44)[70].	 This	 has	 prompted	 us	 to	 experimentally	 verify	 for	 a	 possible	recognition	of	the	A6	peptide	by	the	CD44	antibody	DF1485,	given	that	such	antibody	was	used	in	cellular	assays	to	study	the	mechanism	of	action	of	A6.	To	facilitate	these	binding	studies,	we	synthesized	a	13C-labeled	version	of	A6	and	collected	2D	[13C,1H]-HSQC	 spectra	 of	 such	 agent	 in	 absence	 and	 in	 presence	 of	 the	 antibody	 DF1485.	
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However,	under	these	experimental	conditions,	no	appreciable	binding	was	detected	(Figure	37)	between	A6	and	the	antibody.		Subsequently,	we	also	tested	a	recently	discovered	small	organic	molecule	that	was	 reported	 to	 bind	 the	 recombinant	 CD44	 HA	 binding	 domain	 with	 millimoar	affinity[59].	We	obtained	such	compound	3	(Matrix	Scientific,	Columbia,	SC)	and	tested	it	 at	2	mM	(Figure	 38)	 and	20	mM	(Figure	 39)	 against	 15N-hCD44(21-178)	by	2D	[1H,15N]-sofast-HMQC.	 Several	 significant	 chemical	 shift	 perturbations	 in	 the	 2D	[1H,15N]-sofast-HMQC	 spectrum	 of	 hCD44(21-178)	 were	 observed	 initially	 in	presence	 of	 20	mM	 of	 compound	 3.	 However,	 the	 perturbations	were	 suspiciously	widespread	 for	 such	small	 ligand.	Upon	 further	 investigations	we	noticed	 that	 such	high	concentration	of	compound	3	led	to	a	sizable	increase	of	the	pH,	likely	due	to	the	compound	itself	(having	a	primary	ammine)	or	an	impurity.	Indeed,	recording	again	the	 spectrum	 after	 correcting	 the	 pH	 we	 observed	 that	 there	 was	 no	 significant	evidence	of	binding	(Figure	39).	The	2D	[1H,15N]-sofast-HMQC	of	15N-hCD44(21-178)	at	20	µM	measured	 in	absence	and	presence	of	2	mM	compound	3	are	 reported	 in	
Figure	38.	Furthermore	we	monitored	the	ability	of	compound	3	to	displace	HA8	by	ITC.	In	this	experiment,	ITC	curves	for	the	binding	of	HA8	to	CD44	were	collected	in	absence	 (Figure	 33)	 and	 in	 presence	 of	 up	 to	 55	mM	of	 compound	3.	Also	 by	 this	displacement	assay,	the	presence	of	compound	3,	even	at	such	high	concentration,	did	not	 significantly	 displace	 the	 binding	 between	 CD44	 and	 HA8	 (Figure	 40).	 We	conclude,	unfortunately	that	the	putative	binding	and	HA8	displacement	reported	by	
Liu	et	al.[59]	 using	a	 less	 sensitive	SPR	assay,	may	have	been	a	 result	 of	pH	changes	induced	by	the	compound.	In	 a	 follow-up	 study	 however	 Liu	 et	 al.[73]	 reported	 that	 in	 resolving	 the	 crystal	structure	of	hCD44(20-178),	electron	density	of	an	unidentified	peptide	docked	into	a	
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novel	 hydrophobic	 binding	 pocket	 situated	 on	 the	 opposite	 side	 of	 the	HA	 binding	site.	From	the	electron	density	it	was	possible	only	to	identify	a	valine	residue	as	the	first	amino	acid	of	this	unknown	peptide	located	into	the	small	binding	pocket.	Based	on	this	observations	we	decided	to	perform	a	 further	screening	campaign	using	the	HTS	by	NMR	approach[81].	Aimed	at	identifying	a	possible	CD44	binding	peptide,	we	subsequently	decided	to	screen	a	four-position	combinatorial	library	composed	by	19	natural	amino	acids	(the	20	natural	amino	acids	except	cysteine)	as	building	blocks.	In	 this	 way	 we	 tested	 all	 the	 possible	 combinations	 of	 tetra-peptides,	 including	peptides	 with	 the	 valine	 at	 the	 N-	 and	 C-	 terminal.	 However,	 no	 viable	 hits	 were	detected	 using	 2D	 [1H,15N]-sofast-HMQC	 among	 the	 tested	 76	 mixtures	 (see	Methods).	At	this	point	we	tested	with	the	same	approach	a	tri-peptide	combinatorial	library	assembled	using	46,	natural	and	non-natural,	amino	acids	as	building	blocks.	Based	 on	 the	 evidence	 that	 only	 the	 first	 amino	 acid	 stays	 inside	 the	 new	 binding	pocket,	we	decided	to	screen	only	the	peptides	with	the	first	position	fixed.	Again	we	didn’t	 find	any	peptide	 interacting	with	 the	 target	protein	using	2D	 [1H,15N]-sofast-HMQC.	Finally	we	decided	 to	 conduct	 a	 fragment	 screening	using	NMR	as	 detection	technique	aimed	at	 finding	possibly	new	hits	able	 to	bind	hCD44.	By	screening	of	a	500	 small	 molecule	 fragment	 library	 (Maybridge)	 we	 obtained	 two	 structurally	related	 initial	 hits	 (Figure	 41).	 Starting	 from	 these	 initial	 hits,	 we	 tested	 other	analogs	 (Table	 5)	 that	 resulted	 in	 compound	131B6	 (Figure	 42).	Analyses	of	 data	resulting	 from	 both	 the	 1D	 1H	 aliphatic	 (Figure	 42)	 and	 2D	 [1H,15N]-sofast-HMQC	NMR	experiments	(Figure	43),	concluded	that	the	residues	that	were	most	perturbed	were	 situated	 in	 a	 region	 of	 hCD44(21-178)	 forming	 a	 possible	 back	 pocket	 in	 the	opposite	site	from	where	HA8	binds	and	close	but	different	from	the	pocket	observed	
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by	 Liu	 et	 al.[73].	 From	 the	 chemical	 shift	 perturbations	 we	 could	 obtain	 an	 average	dissociation	 constant	 of	 Kd	 equal	 to	 7.43	 mM	 (Figure	 45).	 For	 both,	 131B6	 and	compound	3[59],	we	also	collected	Saturation	Transfer	Difference	(STD)	spectra.	First	we	 tested	 as	 positive	 control	 HA8	 that	 as	 expected	 gave	 a	 significant	 STD	 effect	(Figure	 48A).	 However,	 when	 we	 ran	 the	 same	 experiment	 with	 131B6	 (Figure	
48B),	 or	 compound	 3	 (Figure	 48C),	 there	 was	 no	 significant	 STD	 effect	 in	 either	compound.	 These	 data	 further	 confirm	 that	 for	 fragments	 with	 fairly	 low	 affinity	ranging	 from	 1	 to	 10	 mM	 a	 protein	 based	 experiment	 (as	 the	 2D	 [1H,15N]-sofast-HMQC	or	the	1D	1H-aliphatic	NMR	experiments)	is	more	sensitive	and	robust	than	a	ligand	based	approach	(as	 the	STD)[77].	To	 further	confirm	the	binding	mode	of	 this	fragment	hit	and	 to	obtain	 further	structural	 information	about	 its	possible	binding	pose	we	recorded	2D	[1H,1H]-NOESY	NMR	spectra	(Figure	46)	for	hCD44	(21-178)	in	absence	and	in	presence	of	compound	131B6.	In	the	presence	of	this	compound,	we	observed	a	cross-peak	between	the	proton	of	the	thiazole	of	131B6	and	the	β-protons	of	leucine	135	that,	from	both	1D	and	2D	NMR	experiments,	was	the	most	perturbed	residue	by	the	compound.	These	data	further	confirmed	that	131B6	is	close	in	space	(<	5	Å)	to	the	leucine	135.	Binding	of	131B6	to	CD44	did	not	affect	the	binding	of	HA8	as	 determined	 by	 NMR	 titration	 with	 2D	 [1H,15N]-sofast-HMQC	 (Figure	 47A	 and	
47B).	 An	important	and	interesting	observation	is	that	the	residues	most	perturbed	upon	 the	 binding	 of	 131B6	 to	 hCD44(21-178)	 spatially	 overlap	 to	 a	 region	 that	encompasses	the	sequence	of	CD44	with	high	homology	to	the	A6	peptide	sequence	(Figure	44).	In	particular,	the	chemical	shift	of	several	residues	within	this	sequence	were	perturbed	from	the	2D	[1H,15N]-sofast-HMQC	spectrum	collected	in	presence	of	131B6.	 As	 previously	 hypothesized,	 this	 homology	 between	 the	 A6	 peptide	 and	 a	
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linear	sequence	within	CD44	may	provide	an	alternative	explanation	for	the	cellular	and	 in	vivo	 	 activity	 of	A6	whereby	A6	may	 function	 as	 a	 decoy	 for	 a	 yet	 unknown	binding	partner	of	CD44[70].		
	
	
	
Figure	 48	 Saturation	 Transfer	 Difference	 (STD)	 experiments	 of	 5	 µM	 hCD44(21-178)	 in	presence	of	400	µM	HA8	(A),	400	µM	compound	131B6	(B)	and,	400	µM	compound	3	(C).	In	all	 the	 spectra	 in	 blue	 is	 represented	 the	 off-resonance	 spectrum,	 in	 red	 the	 on-resonance	and,	in	green	the	STD.		
A 
B 
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	If	this	hypothesis	is	correct,	 ligands	binding	in	proximity	of	this	loop	of	CD44	may	exert	a	biological	activity,	rendering	131B6	a	potentially	interesting	fragment	for	further	 hit	 maturations	 and	 subsequent	 cellular	 assays.	 Hence	 our	 studies	 have	potentially	 significant	 implications	 on	 the	 possible	 mechanism	 of	 A6,	 and	 may	provide	a	new	rationale	for	targeting	a	possible	binding	pocket	on	CD44.		
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Conclusions	
	 CD44	 has	 revealed	 to	 be	 a	 potentially	 very	 interesting	 receptor	 for	pharmacological	intervention	targeting	tumor	metastasis.	However,	further	research	in	the	validation	of	CD44	as	possible	drug	target	is	hampered	by	the	lack	of	suitable	pharmacological	 agents.	 In	 this	 article	we	 characterized	 a	 variety	 of	 putative	 CD44	binding	 agents.	 With	 the	 exception	 of	 an	 antibody	 and	 HA8,	 none	 of	 these	 agents,	including	 the	 clinical	peptide	A6,	 showed	appreciable	binding	 to	 a	 recombinant	HA	binding	 domain	 construct	 of	 CD44.	 However,	 an	 NMR	 guided	 fragment	 screening	revealed	potentially	interesting	fragment	hit	131B6.	The	compound	bound	to	CD44	in	an	area	that	 is	opposite	 to	 the	HA	binding	site	and	 is	composed	by	a	 loop	region	of	CD44	 (loop	 β6-β7)	 that	 presents	 a	 high	 homology	 with	 the	 anti-CD44	 peptide	 A6.	Based	on	these	data,	it	is	tempting	to	speculate	that	A6	may	function	as	a	decoy	for	an	unidentified	 CD44	 binding	 protein	 that	 uses	 loop	 β6-β7	 for	 such	 interactions[70].	Therefore,	 further	optimizations	of	131B6	may	result	 in	 small	molecule	agents	 that	similar	to	A6	may	impair	the	function	of	CD44.																		
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